View Item 

Show simple item record

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder
dc.contributor.authorYatham, Lakshmi N
dc.contributor.authorKennedy, Sidney H
dc.contributor.authorParikh, Sagar V
dc.contributor.authorSchaffer, Ayal
dc.contributor.authorBond, David J
dc.contributor.authorFrey, Benicio N
dc.contributor.authorSharma, Verinder
dc.contributor.authorGoldstein, Benjamin I
dc.contributor.authorRej, Soham
dc.contributor.authorBeaulieu, Serge
dc.contributor.authorAlda, Martin
dc.contributor.authorMacQueen, Glenda
dc.contributor.authorMilev, Roumen V
dc.contributor.authorRavindran, Arun
dc.contributor.authorO’Donovan, Claire
dc.contributor.authorMcIntosh, Diane
dc.contributor.authorLam, Raymond W
dc.contributor.authorVazquez, Gustavo
dc.contributor.authorKapczinski, Flavio
dc.contributor.authorMcIntyre, Roger S
dc.contributor.authorKozicky, Jan
dc.contributor.authorKanba, Shigenobu
dc.contributor.authorLafer, Beny
dc.contributor.authorSuppes, Trisha
dc.contributor.authorCalabrese, Joseph R
dc.contributor.authorVieta, Eduard
dc.contributor.authorMalhi, Gin
dc.contributor.authorPost, Robert M
dc.contributor.authorBerk, Michael
dc.date.accessioned2018-04-04T18:51:57Z
dc.date.available2019-05-13T14:45:26Zen
dc.date.issued2018-03
dc.identifier.citationYatham, Lakshmi N; Kennedy, Sidney H; Parikh, Sagar V; Schaffer, Ayal; Bond, David J; Frey, Benicio N; Sharma, Verinder; Goldstein, Benjamin I; Rej, Soham; Beaulieu, Serge; Alda, Martin; MacQueen, Glenda; Milev, Roumen V; Ravindran, Arun; O’Donovan, Claire; McIntosh, Diane; Lam, Raymond W; Vazquez, Gustavo; Kapczinski, Flavio; McIntyre, Roger S; Kozicky, Jan; Kanba, Shigenobu; Lafer, Beny; Suppes, Trisha; Calabrese, Joseph R; Vieta, Eduard; Malhi, Gin; Post, Robert M; Berk, Michael (2018). "Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder." Bipolar Disorders 20(2): 97-170.
dc.identifier.issn1398-5647
dc.identifier.issn1399-5618
dc.identifier.urihttps://hdl.handle.net/2027.42/142934
dc.publisherAmerican Psychiatric Publishing
dc.publisherWiley Periodicals, Inc.
dc.titleCanadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPsychology
dc.subject.hlbtoplevelSocial Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142934/1/bdi12609.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142934/2/bdi12609_am.pdf
dc.identifier.doi10.1111/bdi.12609
dc.identifier.sourceBipolar Disorders
dc.identifier.citedreferenceHwang YJ, Dixon SN, Reiss JP, et al. Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population‐based cohort study. Ann Intern Med. 2014; 161: 242 ‐ 8.
dc.identifier.citedreferenceKupka RW, Luckenbaugh DA, Post RM, Leverich GS, Nolen WA. Rapid and non‐rapid cycling bipolar disorder: a meta‐analysis of clinical studies. J Clin Psychiatry. 2003; 64: 1483 ‐ 94.
dc.identifier.citedreferenceBendz H, Sjodin I, Toss G, Berglund K. Hyperparathyroidism and long‐term lithium therapy–a cross‐sectional study and the effect of lithium withdrawal. J Intern Med. 1996; 240: 357 ‐ 65.
dc.identifier.citedreferenceJoffe H, Cohen LS, Suppes T, et al. Valproate is associated with new‐onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiat. 2006; 59: 1078 ‐ 86.
dc.identifier.citedreferenceZhang L, Li H, Li S, Zou X. Reproductive and metabolic abnormalities in women taking valproate for bipolar disorder: a meta‐analysis. Eur J Obstet Gynecol Reprod Biol. 2016; 202: 26 ‐ 31.
dc.identifier.citedreferenceJoffe H, Cohen LS, Suppes T, et al. Longitudinal follow‐up of reproductive and metabolic features of valproate‐associated polycystic ovarian syndrome features: a preliminary report. Biol Psychiatry. 2006; 60: 1378 ‐ 81.
dc.identifier.citedreferenceMontejo AL, Arango C, Bernardo M, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol. 2017; 45: 25 ‐ 34.
dc.identifier.citedreferenceMontejo AL, Arango C, Bernardo M, et al. Spanish consensus on the risks and detection of antipsychotic drug‐related hyperprolactinaemia. Rev Psiquiatr Salud Ment. 2016; 9: 158 ‐ 73.
dc.identifier.citedreferencePacchiarotti I, Murru A, Kotzalidis GD, et al. Hyperprolactinemia and medications for bipolar disorder: systematic review of a neglected issue in clinical practice. Eur Neuropsychopharmacol. 2015; 25: 1045 ‐ 59.
dc.identifier.citedreferenceCullen B, Ward J, Graham NA, et al. Prevalence and correlates of cognitive impairment in euthymic adults with bipolar disorder: a systematic review. J Affect Disord. 2016; 205: 165 ‐ 81.
dc.identifier.citedreferenceGoswami U, Sharma A, Varma A, et al. The neurocognitive performance of drug‐free and medicated euthymic bipolar patients do not differ. Acta Psychiatr Scand. 2009; 120: 456 ‐ 63.
dc.identifier.citedreferenceDias VV, Balanza‐Martinez V, Soeiro‐de‐Souza MG, et al. Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatr Scand. 2012; 126: 315 ‐ 31.
dc.identifier.citedreferenceMalhi GS, McAulay C, Gershon S, et al. The lithium battery: assessing the neurocognitive profile of lithium in bipolar disorder. Bipolar Disord. 2016; 18: 102 ‐ 15.
dc.identifier.citedreferenceTohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry. 1999; 156: 702 ‐ 9.
dc.identifier.citedreferenceTohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania – a double‐blind, placebo‐controlled study. Arch Gen Psychiatry. 2000; 57: 841 ‐ 9.
dc.identifier.citedreferenceKeck PE, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three‐week, placebo‐controlled, double‐blind, randomized trial. Am J Psychiatry. 2003; 160: 741 ‐ 8.
dc.identifier.citedreferenceTohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002; 159: 1011 ‐ 7.
dc.identifier.citedreferenceZajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2002; 63: 1148 ‐ 55.
dc.identifier.citedreferenceKetter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology. 1999; 53: S53 ‐ 67.
dc.identifier.citedreferenceMacritchie KA, Geddes JR, Scott J, Haslam DR, Goodwin GM. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev. 2001;( 3 ): Cd003196.
dc.identifier.citedreferenceGoodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo‐controlled 18‐month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry. 2004; 65: 432 ‐ 41.
dc.identifier.citedreferenceCheng M, Tang X, Wen S, Yue J, Wang H. Valproate (VPA)‐associated hyperammonemic encephalopathy independent of elevated serum VPA levels: 21 cases in China from May 2000 to May 2012. Compr Psychiatry. 2013; 54: 562 ‐ 7.
dc.identifier.citedreferenceMaj M, Starace F, Nolfe G, Kemali D. Minimum plasma lithium levels required for effective prophylaxis in DSM‐III bipolar disorder – a prospective‐study. Pharmacopsychiatry. 1986; 19: 420 ‐ 3.
dc.identifier.citedreferenceVestergaard P. How does the patient prefer his lithium treatment. Pharmacopsychiatry. 1985; 18: 223 ‐ 4.
dc.identifier.citedreferenceWirshing WC. Movement disorders associated with neuroleptic treatment. J Clin Psychiatry. 2001; 62: 15 ‐ 8.
dc.identifier.citedreferenceChue P, Kovacs CS. Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management. Bipolar Disord. 2003; 5: 62 ‐ 79.
dc.identifier.citedreferenceMiller DS, Yatham LN, Lam RW. Comparative efficacy of typical and atypical antipsychotics as add‐on therapy to mood stabilizers in the treatment of acute mania. J Clin Psychiatry. 2001; 62: 975 ‐ 80.
dc.identifier.citedreferenceRudolph JL, Gardner KF, Gramigna GD, McGlinchey RE. Antipsychotics and oropharyngeal dysphagia in hospitalized older patients. J Clin Psychopharmacol. 2008; 28: 532 ‐ 5.
dc.identifier.citedreferenceLee JC, Takeshita J. Antipsychotic‐induced dysphagia: a case report. Prim Care Companion CNS Disord. 2015; 17. https://doi.org/10.4088/PCC.15l01792.
dc.identifier.citedreferenceSarkar S, Gupta N. Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association. BJPsych Bull. 2017; 41: 211 ‐ 6.
dc.identifier.citedreferenceTse L, Barr AM, Scarapicchia V, Vila‐Rodriguez F. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol. 2015; 13: 395 ‐ 406.
dc.identifier.citedreferenceKwok JS, Chan TY. Recurrent heat‐related illnesses during antipsychotic treatment. Ann Pharmacother. 2005; 39: 1940 ‐ 2.
dc.identifier.citedreferenceKreuzer P, Landgrebe M, Wittmann M, et al. Hypothermia associated with antipsychotic drug use: a clinical case series and review of current literature. J Clin Pharmacol. 2012; 52: 1090 ‐ 7.
dc.identifier.citedreferenceGuberman AH, Besag FMC, Brodie MJ, et al. Lamotrigine‐associated rash: risk benefit considerations in adults and children. Epilepsia. 1999; 40: 985 ‐ 91.
dc.identifier.citedreferenceMessenheimer J, Mullens EL, Giorgi L, Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Saf. 1998; 18: 281 ‐ 96.
dc.identifier.citedreferenceRzany B, Correia O, Kelly JP, et al. Risk of Stevens‐Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case‐control study. Lancet. 1999; 353: 2190 ‐ 4.
dc.identifier.citedreferenceYeung CK, Chan HH. Cutaneous adverse effects of lithium: epidemiology and management. Am J Clin Dermatol. 2004; 5: 3 ‐ 8.
dc.identifier.citedreferenceMezuk B, Morden NE, Ganoczy D, Post EP, Kilbourne AM. Anticonvulsant use, bipolar disorder, and risk of fracture among older adults in the Veterans Health Administration. Am J Geriatr Psychiatry. 2010; 18: 245 ‐ 55.
dc.identifier.citedreferenceWilliams LJ, Henry MJ, Berk M, et al. Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol. 2008; 23: 84 ‐ 7.
dc.identifier.citedreferenceWilliams LJ, Pasco JA, Jackson H, et al. Depression as a risk factor for fracture in women: a 10 year longitudinal study. J Affect Disord. 2016; 192: 34 ‐ 40.
dc.identifier.citedreferenceWilliams LJ, Bjerkeset O, Langhammer A, et al. The association between depressive and anxiety symptoms and bone mineral density in the general population: the HUNT Study. J Affect Disord. 2011; 131: 164 ‐ 71.
dc.identifier.citedreferenceACOG Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetricians‐Gynecologists. Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008; 111: 1001 ‐ 20.
dc.identifier.citedreferenceHale TW, Rowe HE. Medications and Mother’s Milk. New York, NY: Springer Publishing Company, LLC; 2017.
dc.identifier.citedreferenceKusumakar V, Yatham LN, Haslam DRS, et al. The foundations of effective management of bipolar disorder. Can J Psychiatry. 1997; 42: S69 ‐ S73.
dc.identifier.citedreferenceYatham LN, Kennedy SH, O’Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006; 8: 721 ‐ 39.
dc.identifier.citedreferenceYatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009; 11: 225 ‐ 55.
dc.identifier.citedreferenceYatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013; 15: 1 ‐ 44.
dc.identifier.citedreferenceDiagnostic and Statistical Manual of Mental Disorders: DSM‐5. 5th edn. Arlington, VA: American Psychiatric Publishing; 2013.
dc.identifier.citedreferenceMerikangas KR, Jin R, He J‐P, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011; 68: 241 ‐ 51.
dc.identifier.citedreferenceMcDonald KC, Bulloch AGM, Duffy A, et al. Prevalence of bipolar I and II disorder in Canada. Can J Psychiatry. 2015; 60: 151 ‐ 6.
dc.identifier.citedreferenceBauer M, Glenn T, Alda M, et al. Influence of birth cohort on age of onset cluster analysis in bipolar I disorder. Eur Psychiatry. 2015; 30: 99 ‐ 105.
dc.identifier.citedreferenceBellivier F, Etain B, Malafosse A, et al. Age at onset in bipolar I affective disorder in the USA and Europe. World J Biol Psychiatry. 2014; 15: 369 ‐ 76.
dc.identifier.citedreferenceJoslyn C, Hawes DJ, Hunt C, Mitchell PB. Is age of onset associated with severity, prognosis, and clinical features in bipolar disorder? A meta‐analytic review Bipolar Disord. 2016; 18: 389 ‐ 403.
dc.identifier.citedreferenceSami M, Khan H, Nilforooshan R. Late onset mania as an organic syndrome: a review of case reports in the literature. J Affect Disord. 2015; 188: 226 ‐ 31.
dc.identifier.citedreferenceJudd LL, Akiskal HS, Schettler PJ, et al. The long‐term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002; 59: 530 ‐ 7.
dc.identifier.citedreferenceJudd LL, Schettler PJ, Akiskal HS, et al. Long‐term symptomatic status of bipolar I vs. bipolar II disorders. Int J Neuropsychopharmacol. 2003; 6: 127 ‐ 37.
dc.identifier.citedreferenceJudd LL, Schettler PJ, Solomon DA, et al. Psychosocial disability and work role function compared across the long‐term course of bipolar I, bipolar II and unipolar major depressive disorders. J Affect Disord. 2008; 108: 49 ‐ 58.
dc.identifier.citedreferenceGutierrez‐Rojas L, Gurpegui M, Ayuso‐Mateos JL, Gutierrez‐Ariza JA, Ruiz‐Veguilla M, Jurado D. Quality of life in bipolar disorder patients: a comparison with a general population sample. Bipolar Disord. 2008; 10: 625 ‐ 34.
dc.identifier.citedreferenceBonnin CM, Sanchez‐Moreno J, Martinez‐Aran A, et al. Subthreshold symptoms in bipolar disorder: impact on neurocognition, quality of life and disability. J Affect Disord. 2012; 136: 650 ‐ 9.
dc.identifier.citedreferenceMaina G, Albert U, Bellodi L, et al. Health‐related quality of life in euthymic bipolar disorder patients: differences between bipolar I and II subtypes. J Clin Psychiatry. 2007; 68: 207 ‐ 12.
dc.identifier.citedreferenceMichalak EE, Murray G, Crest BD. Development of the QoL.BD: a disorder‐specific scale to assess quality of life in bipolar disorder. Bipolar Disord. 2010; 12: 727 ‐ 40.
dc.identifier.citedreferenceVan Rheenen TE, Rossell SL. Objective and subjective psychosocial functioning in bipolar disorder: an investigation of the relative importance of neurocognition, social cognition and emotion regulation. J Affect Disord. 2014; 162: 134 ‐ 41.
dc.identifier.citedreferenceRosa AR, Gonzalez‐Ortega I, Gonzalez‐Pinto A, et al. One‐year psychosocial functioning in patients in the early vs. late stage of bipolar disorder. Acta Psychiatr Scand. 2012; 125: 335 ‐ 41.
dc.identifier.citedreferenceOldis M, Murray G, Macneil CA, et al. Trajectory and predictors of quality of life in first episode psychotic mania. J Affect Disord. 2016; 195: 148 ‐ 55.
dc.identifier.citedreferenceMichalak EE, Torres IJ, Bond DJ, Lam RW, Yatham LN. The relationship between clinical outcomes and quality of life in first‐episode mania: a longitudinal analysis. Bipolar Disord. 2013; 15: 188 ‐ 98.
dc.identifier.citedreferenceSimonsen C, Sundet K, Vaskinn A, et al. Psychosocial function in schizophrenia and bipolar disorder: relationship to neurocognition and clinical symptoms. J Int Neuropsychol Soc. 2010; 16: 771 ‐ 83.
dc.identifier.citedreferenceFerrari AJ, Stockings E, Khoo JP, et al. The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. Bipolar Disord. 2016; 18: 440 ‐ 50.
dc.identifier.citedreferenceGore FM, Bloem PJN, Patton GC, et al. Global burden of disease in young people aged 10‐24 years: a systematic analysis. Lancet. 2011; 377: 2093 ‐ 102.
dc.identifier.citedreferenceJin HJ, McCrone P. Cost‐of‐illness studies for bipolar disorder: systematic review of international studies. Pharmacoeconomics. 2015; 33: 341 ‐ 53.
dc.identifier.citedreferenceMalhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015; 49: 1087 ‐ 206.
dc.identifier.citedreferenceKessing LV, Andersen PK. Evidence for clinical progression of unipolar and bipolar disorders. Acta Psychiatr Scand. 2017; 135: 51 ‐ 64.
dc.identifier.citedreferencePassos IC, Mwangi B, Vieta E, Berk M, Kapczinski F. Areas of controversy in neuroprogression in bipolar disorder. Acta Psychiatr Scand. 2016; 134: 91 ‐ 103.
dc.identifier.citedreferenceBerk M, Post R, Ratheesh A, et al. Staging in bipolar disorder: from theoretical framework to clinical utility. World Psychiatry. 2017; 16: 236 ‐ 44.
dc.identifier.citedreferenceKapczinski F, Magalhaes PV, Balanza‐Martinez V, et al. Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report. Acta Psychiatr Scand. 2014; 130: 354 ‐ 63.
dc.identifier.citedreferenceAlda M, Kapczinski F. Staging model raises fundamental questions about the nature of bipolar disorder. J Psychiatry Neurosci. 2016; 41: 291 ‐ 3.
dc.identifier.citedreferenceDuffy A, Goodday S, Passos IC, Kapczinski F. Changing the bipolar illness trajectory. Lancet Psychiatry. 2017; 4: 11 ‐ 3.
dc.identifier.citedreferenceHirschfeld RMA, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic‐Depressive Association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003; 64: 161 ‐ 74.
dc.identifier.citedreferenceScott J, Leboyer M. Consequences of delayed diagnosis of bipolar disorders. Encephale. 2011; 37: S173 ‐ S5.
dc.identifier.citedreferenceKnezevic V, Nedic A. Influence of misdiagnosis on the course of bipolar disorder. Eur Rev Med Pharmacol Sci. 2013; 17: 1542 ‐ 5.
dc.identifier.citedreferenceAltamura AC, Buoli M, Caldiroli A, et al. Misdiagnosis, duration of untreated illness (DUI) and outcome in bipolar patients with psychotic symptoms: a naturalistic study. J Affect Disord. 2015; 182: 70 ‐ 5.
dc.identifier.citedreferenceMitchell PB, Goodwin GM, Johnson GF, Hirschfeld RMA. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord. 2008; 10: 144 ‐ 52.
dc.identifier.citedreferenceSchaffer A, Cairney J, Veldhuizen S, Kurdyak P, Cheung A, Levitt A. A population‐based analysis of distinguishers of bipolar disorder from major depressive disorder. J Affect Disord. 2010; 125: 103 ‐ 10.
dc.identifier.citedreferenceGonzalez‐Pinto A, Gutierrez M, Mosquera F, et al. First episode in bipolar disorder: misdiagnosis and psychotic symptoms. J Affect Disord. 1998; 50: 41 ‐ 4.
dc.identifier.citedreferenceZimmerman M, Ruggero CJ, Chelminski I, Young D. Is bipolar disorder overdiagnosed? J Clin Psychiatry. 2008; 69: 935 ‐ 40.
dc.identifier.citedreferenceGhouse AA, Sanches M, Zunta‐Soares G, Swann AC, Soares JC. Overdiagnosis of bipolar disorder: a critical analysis of the literature. ScientificWorldJournal. 2013; 2013: 1 ‐ 5.
dc.identifier.citedreferenceCyprien F, Guillaume S, Jaussent I, et al. Impact of axis‐I comorbidity and suicidal behavior disorders on sensitivity and specificity of the Mood Disorder Questionnaire in complex depressed inpatients. Compr Psychiatry. 2014; 55: 876 ‐ 82.
dc.identifier.citedreferenceMeyer F, Meyer TD. The misdiagnosis of bipolar disorder as a psychotic disorder: some of its causes and their influence on therapy. J Affect Disord. 2009; 112: 174 ‐ 83.
dc.identifier.citedreferenceMerikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12‐month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry. 2007; 64: 543 ‐ 52.
dc.identifier.citedreferenceWebb RT, Lichtenstein P, Larsson H, Geddes JR, Fazel S. Suicide, hospital‐presenting suicide attempts, and criminality in bipolar disorder: examination of risk for multiple adverse outcomes. J Clin Psychiatry. 2014; 75: e809 ‐ 16.
dc.identifier.citedreferenceSchaffer A, Isometsa ET, Tondo L, et al. Epidemiology, neurobiology and pharmacological interventions related to suicide deaths and suicide attempts in bipolar disorder: Part I of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder. Aust N Z J Psychiatry. 2015; 49: 785 ‐ 802.
dc.identifier.citedreferenceTondo L, Lepri B, Baldessarini RJ. Suicidal risks among 2826 sardinian major affective disorder patients. Acta Psychiatr Scand. 2007; 116: 419 ‐ 28.
dc.identifier.citedreferenceSinghal A, Ross J, Seminog O, Hawton K, Goldacre MJ. Risk of self‐harm and suicide in people with specific psychiatric and physical disorders: comparisons between disorders using English national record linkage. J R Soc Med. 2014; 107: 194 ‐ 204.
dc.identifier.citedreferenceSchaffer A, Isometsa ET, Azorin JM, et al. A review of factors associated with greater likelihood of suicide attempts and suicide deaths in bipolar disorder: Part II of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder. Aust N Z J Psychiatry. 2015; 49: 1006 ‐ 20.
dc.identifier.citedreferenceMarangell LB, Bauer MS, Dennehy EB, et al. Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 years. Bipolar Disord. 2006; 8: 566 ‐ 75.
dc.identifier.citedreferenceKeks NA, Hill C, Sundram S, et al. Evaluation of treatment in 35 cases of bipolar suicide. Aust N Z J Psychiatry. 2009; 43: 503 ‐ 8.
dc.identifier.citedreferenceCarter G, Milner A, McGill K, Pirkis J, Kapur N, Spittal MJ. Predicting suicidal behaviours using clinical instruments: systematic review and meta‐analysis of positive predictive values for risk scales. Br J Psychiatry. 2017; 210: 387.
dc.identifier.citedreferenceSmith KA, Cipriani A. Lithium and suicide in mood disorders: updated meta‐review of the scientific literature. Bipolar Disord. 2017; 19: 575 ‐ 86.
dc.identifier.citedreferenceSchaffer A, Sinyor M, Howlett A, Cheung A. Suicide by overdose in a bipolar disorder cohort. Bipolar Disord. 2012; 14: 122.
dc.identifier.citedreferenceWagner EH. Chronic disease management: what will it take to improve care for chronic illness? Eff Clin Pract. 1998; 1: 2 ‐ 4.
dc.identifier.citedreferenceParikh SV, Kennedy SH. Integration of Patient, Provider, and Systems Treatment Approaches in Bipolar Disorder: Where Evidence Meets Practice Reality. West Sussex, England: John Wiley & Sons Ltd; 2004.
dc.identifier.citedreferenceConsensus Statement on Improving Mental Health Transitions. Alberta: Institute of Health Economics; 2014.
dc.identifier.citedreferenceSylvia LG, Hay A, Ostacher MJ, et al. Association between therapeutic alliance, care satisfaction, and pharmacological adherence in bipolar disorder. J Clin Psychopharmacol. 2013; 33: 343 ‐ 50.
dc.identifier.citedreferenceStrauss JL, Johnson SL. Role of treatment alliance in the clinical management of bipolar disorder: stronger alliances prospectively predict fewer manic symptoms. Psychiatry Res. 2006; 145: 215 ‐ 23.
dc.identifier.citedreferenceElwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012; 27: 1361 ‐ 7.
dc.identifier.citedreferenceDrake RE, Cimpean D, Torrey WC. Shared decision making in mental health: prospects for personalized medicine. Dialogues Clin Neurosci. 2009; 11: 455 ‐ 63.
dc.identifier.citedreferenceKessing LV, Hansen HV, Hvenegaard A, et al. Treatment in a specialised out‐patient mood disorder clinic v. standard out‐patient treatment in the early course of bipolar disorder: randomised clinical trial. Br J Psychiatry. 2013; 202: 212 ‐ 9.
dc.identifier.citedreferenceDenicoff KD, Ali SO, Sollinger AB, Smith‐Jackson EE, Leverich GS, Post RM. Utility of the daily prospective National Institute of Mental Health Life‐Chart Method (NIMH‐LCM‐p) ratings in clinical trials of bipolar disorder. Depress Anxiety. 2002; 15: 1 ‐ 9.
dc.identifier.citedreferencevan Bendegem MA, van den Heuvel S, Kramer LJ, Goossens PJJ. Attitudes of patients with bipolar disorder toward the life chart methodology: a phenomenological study. J Am Psychiatr Nurs Assoc. 2014; 20: 376 ‐ 85.
dc.identifier.citedreferenceLieberman DZ, Kelly TF, Douglas L, Goodwin FK. A randomized comparison of online and paper mood charts for people with bipolar disorder. J Affect Disord. 2010; 124: 85 ‐ 9.
dc.identifier.citedreferenceHidalgo‐Mazzei D, Mateu A, Reinares M, et al. Self‐monitoring and psychoeducation in bipolar patients with a smart‐phone application (SIMPLe) project: design, development and studies protocols. BMC Psychiatry. 2015; 15: 52.
dc.identifier.citedreferenceHidalgo‐Mazzei D, Mateu A, Reinares M, Matic A, Vieta E, Colom F. Internet‐based psychological interventions for bipolar disorder: review of the present and insights into the future. J Affect Disord. 2015; 188: 1 ‐ 13.
dc.identifier.citedreferenceHidalgo‐Mazzei D, Mateu A, Reinares M, et al. Psychoeducation in bipolar disorder with a SIMPLe smartphone application: feasibility, acceptability and satisfaction. J Affect Disord. 2016; 200: 58 ‐ 66.
dc.identifier.citedreferenceHawke LD, Parikh SV, Michalak EE. Stigma and bipolar disorder: a review of the literature. J Affect Disord. 2013; 150: 181 ‐ 91.
dc.identifier.citedreferenceYanos PT, Lucksted A, Drapalski AL, Roe D, Lysaker P. Interventions targeting mental health self‐stigma: a review and comparison. Psychiatr Rehabil J. 2015; 38: 171 ‐ 8.
dc.identifier.citedreferenceReinares M, Sanchez‐Moreno J, Fountoulakis KN. Psychosocial interventions in bipolar disorder: what, for whom, and when. J Affect Disord. 2014; 156: 46 ‐ 55.
dc.identifier.citedreferenceMurray G, Leitan ND, Thomas N, et al. Towards recovery‐oriented psychosocial interventions for bipolar disorder: quality of life outcomes, stage‐sensitive treatments, and mindfulness mechanisms. Clin Psychol Rev. 2017; 52: 148 ‐ 63.
dc.identifier.citedreferenceSmith D, Jones I, Simpson S. Psychoeducation for bipolar disorder. Adv Psychiatr Treat. 2010; 16: 147.
dc.identifier.citedreferenceSalcedo S, Gold AK, Sheikh S, et al. Empirically supported psychosocial interventions for bipolar disorder: current state of the research. J Affect Disord. 2016; 201: 203 ‐ 14.
dc.identifier.citedreferenceNorcross JC, Wampold BE. Evidence‐based therapy relationships: research conclusions and clinical practices. Psychotherapy (Chic). 2011; 48: 98 ‐ 102.
dc.identifier.citedreferenceColom F, Vieta E. Psychoeducation Manual for Bipolar Disorders. Cambridge, UK: Cambridge University Press; 2006.
dc.identifier.citedreferenceBauer M, McBride L. Structured Group Psychotherapy for Bipolar Disorder. The Life Goals Program 2ed. Berlin, Germany: Springer; 2003.
dc.identifier.citedreferenceOud M, Mayo‐Wilson E, Braidwood R, et al. Psychological interventions for adults with bipolar disorder: systematic review and meta‐analysis. Br J Psychiatry. 2016; 208: 213 ‐ 22.
dc.identifier.citedreferenceBond K, Anderson IM. Psychoeducation for relapse prevention in bipolar disorder: a systematic review of efficacy in randomized controlled trials. Bipolar Disord. 2015; 17: 349 ‐ 62.
dc.identifier.citedreferenceParikh SV, Zaretsky A, Beaulieu S, et al. A randomized controlled trial of psychoeducation or cognitive‐behavioral therapy in bipolar disorder: a Canadian Network for Mood and Anxiety treatments (CANMAT) Study. J Clin Psychiatry. 2012; 73: 803 ‐ 10.
dc.identifier.citedreferenceParikh SV, Hawke LD, Zaretsky A, et al. Psychosocial interventions for bipolar disorder and coping style modification: similar clinical outcomes, similar mechanisms? Can J Psychiatry. 2013; 58: 482 ‐ 6.
dc.identifier.citedreferenceParikh SV, Hawke LD, Velyvis V, et al. Combined treatment: impact of optimal psychotherapy and medication in bipolar disorder. Bipolar Disord. 2015; 17: 86 ‐ 96.
dc.identifier.citedreferenceMiklowitz DJ, Otto MW, Frank E, et al. Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9‐month randomized controlled trial. Am J Psychiatry. 2007; 164: 1340 ‐ 7.
dc.identifier.citedreferenceLam DH, Watkins ER, Hayward P, et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder – Outcome of the first year. Arch Gen Psychiatry. 2003; 60: 145 ‐ 52.
dc.identifier.citedreferenceScott J, Paykel E, Morriss R, et al. Cognitive‐behavioural therapy for severe and recurrent bipolar disorders – Randomised controlled trial. Br J Psychiatry. 2006; 188: 313 ‐ 20.
dc.identifier.citedreferenceLynch D, Laws KR, McKenna PJ. Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta‐analytical review of well‐controlled trials. Psychol Med. 2010; 40: 9 ‐ 24.
dc.identifier.citedreferenceYe BY, Jiang ZY, Li X, et al. Effectiveness of cognitive behavioral therapy in treating bipolar disorder: an updated meta‐analysis with randomized controlled trials. Psychiatry Clin Neurosci. 2016; 70: 351 ‐ 61.
dc.identifier.citedreferenceSzentagotai A, David D. The efficacy of cognitive‐behavioral therapy in bipolar disorder: a quantitative meta‐analysis. J Clin Psychiatry. 2010; 71: 66 ‐ 72.
dc.identifier.citedreferenceJones SH, Smith G, Mulligan LD, et al. Recovery‐focused cognitive‐behavioural therapy for recent‐onset bipolar disorder: randomised controlled pilot trial. Br J Psychiatry. 2015; 206: 58 ‐ 66.
dc.identifier.citedreferenceGomes BC, Abreu LN, Brietzke E, et al. A randomized controlled trial of cognitive behavioral group therapy for bipolar disorder. Psychother Psychosom. 2011; 80: 144 ‐ 50.
dc.identifier.citedreferenceCuijpers P. Are all psychotherapies equally effective in the treatment of adult depression? The lack of statistical power of comparative outcome studies. Evid Based Ment Health. 2016; 19: 39 ‐ 42.
dc.identifier.citedreferenceMiklowitz DJ, Goldstein MJ. Bipolar Disorder: A Family‐Focused Treatment Approach. New York, NY: Guilford Publications; 1997.
dc.identifier.citedreferenceMiklowitz DJ, Otto MW, Frank E, et al. Psychosocial treatments for bipolar depression – A 1‐year randomized trial from the systematic treatment enhancement program. Arch Gen Psychiatry. 2007; 64: 419 ‐ 27.
dc.identifier.citedreferenceMiklowitz DJ, Chung B. Family‐focused therapy for bipolar disorder: reflections on 30 years of research. Fam Process. 2016; 55: 483 ‐ 99.
dc.identifier.citedreferenceMcMahon K, Herr NR, Zerubavel N, Hoertel N, Neacsiu AD. Psychotherapeutic treatment of bipolar depression. Psychiatr Clin North Am. 2016; 39: 35 ‐ 56.
dc.identifier.citedreferenceHaynes PL, Gengler D, Kelly M. Social rhythm therapies for mood disorders: an update. Curr Psychiatry Rep. 2016; 18: 75.
dc.identifier.citedreferenceFrank E, Kupfer DJ, Thase ME, et al. Two‐year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry. 2005; 62: 996 ‐ 1004.
dc.identifier.citedreferenceInder ML, Crowe MT, Luty SE, et al. Randomized, controlled trial of Interpersonal and Social Rhythm Therapy for young people with bipolar disorder. Bipolar Disord. 2015; 17: 128 ‐ 38.
dc.identifier.citedreferenceSwartz HA, Levenson JC, Frank E. Psychotherapy for bipolar II disorder: the role of interpersonal and social rhythm therapy. Prof Psychol Res Pr. 2012; 43: 145 ‐ 53.
dc.identifier.citedreferenceBouwkamp CG, de Kruiff ME, van Troost TM, et al. Interpersonal and social rhythm group therapy for patients with bipolar disorder. Int J Group Psychother. 2013; 63: 97 ‐ 115.
dc.identifier.citedreferenceHoberg AA, Vickers KS, Ericksen J, et al. Feasibility evaluation of an interpersonal and social rhythm therapy group delivery model. Arch Psychiatr Nurs. 2013; 27: 271 ‐ 7.
dc.identifier.citedreferenceSwartz HA, Frank E, O’Toole K, et al. Implementing interpersonal and social rhythm therapy for mood disorders across a continuum of care. Psychiatr Serv. 2011; 62: 1377 ‐ 80.
dc.identifier.citedreferenceParikh VS, Velyvis V. Psychosocial Interventions in Bipolar Disorder: Theories, Mechanisms and Key Clinical Trials. Cambridge, UK: Cambridge University Press; 2010.
dc.identifier.citedreferenceProudfoot JG, Jayawant A, Whitton AE, et al. Mechanisms underpinning effective peer support: a qualitative analysis of interactions between expert peers and patients newly‐diagnosed with bipolar disorder. BMC Psychiatry. 2012; 12: 196.
dc.identifier.citedreferenceLloyd‐Evans B, Mayo‐Wilson E, Harrison B, et al. A systematic review and meta‐analysis of randomised controlled trials of peer support for people with severe mental illness. BMC Psychiatry. 2014; 14: 12.
dc.identifier.citedreferenceChinman M, George P, Dougherty RH, et al. Peer support services for individuals with serious mental illnesses: assessing the evidence. Psychiatr Serv. 2014; 65: 429 ‐ 41.
dc.identifier.citedreferenceMahlke CI, Priebe S, Heumann K, Daubmann A, Wegscheider K, Bock T. Effectiveness of one‐to‐one peer support for patients with severe mental illness – a randomised controlled trial. Eur Psychiatry. 2017; 42: 103 ‐ 10.
dc.identifier.citedreferenceCabassa LJ, Camacho D, Velez‐Grau CM, Stefancic A. Peer‐based health interventions for people with serious mental illness: a systematic literature review. J Psychiatr Res. 2017; 84: 80 ‐ 9.
dc.identifier.citedreferenceMorriss R, Lobban F, Riste L, et al. Clinical effectiveness and acceptability of structured group psychoeducation versus optimised unstructured peer support for patients with remitted bipolar disorder (PARADES): a pragmatic, multicentre, observer‐blind, randomised controlled superiority trial. Lancet Psychiatry. 2016; 3: 1029 ‐ 38.
dc.identifier.citedreferenceNaslund JA, Grande SW, Aschbrenner KA, Elwyn G. Naturally occurring peer support through social media: the experiences of individuals with severe mental illness using YouTube. PLoS ONE. 2014; 9: e110171.
dc.identifier.citedreferenceNaslund JA, Aschbrenner KA, Bartels SJ. How people with serious mental illness use smartphones, mobile apps, and social media. Psychiatr Rehabil J. 2016; 39: 364 ‐ 7.
dc.identifier.citedreferenceReinares M, Colom F, Sanchez‐Moreno J, et al. Impact of caregiver group psychoeducation on the course and outcome of bipolar patients in remission: a randomized controlled trial. Bipolar Disord. 2008; 10: 511 ‐ 9.
dc.identifier.citedreferenceBerk L, Berk M, Dodd S, Kelly C, Cvetkovski S, Jorm AF. Evaluation of the acceptability and usefulness of an information website for caregivers of people with bipolar disorder. BMC Med. 2013; 11: 162.
dc.identifier.citedreferencePerich T, Manicavasagar V, Mitchell PB, Ball JR, Hadzi‐Pavlovic D. A randomized controlled trial of mindfulness‐based cognitive therapy for bipolar disorder. Acta Psychiatr Scand. 2013; 127: 333 ‐ 43.
dc.identifier.citedreferenceIves‐Deliperi VL, Howells F, Stein DJ, Meintjes EM, Horn N. The effects of mindfulness‐based cognitive therapy in patients with bipolar disorder: a controlled functional MRI investigation. J Affect Disord. 2013; 150: 1152 ‐ 7.
dc.identifier.citedreferenceTorrent C, Bonnin Cdel M, Martinez‐Aran A, et al. Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. Am J Psychiatry. 2013; 170: 852 ‐ 9.
dc.identifier.citedreferenceSole B, Jimenez E, Torrent C, et al. Cognitive impairment in bipolar disorder: treatment and prevention strategies. Int J Neuropsychopharmacol. 2017; 20: 670 ‐ 680.
dc.identifier.citedreferenceLewandowski KE, Sperry SH, Cohen BM, et al. Treatment to enhance cognition in bipolar disorder (TREC‐BD): efficacy of a randomized controlled trial of cognitive remediation versus active control. J Clin Psychiatry. 2017; 78: e1242 ‐ e1249.
dc.identifier.citedreferenceParikh SV, Huniewicz P. E‐health: an overview of the uses of the Internet, social media, apps, and websites for mood disorders. Curr Opin Psychiatry. 2015; 28: 13 ‐ 7.
dc.identifier.citedreferenceLeitan ND, Michalak EE, Berk L, Berk M, Murray G. Optimizing delivery of recovery‐oriented online self‐management strategies for bipolar disorder: a review. Bipolar Disord. 2015; 17: 115 ‐ 27.
dc.identifier.citedreferenceYoung AH, Eberhard J. Evaluating depressive symptoms in mania: a naturalistic study of patients with bipolar disorder. Neuropsychiatr Dis Treat. 2015; 11: 1137 ‐ 43.
dc.identifier.citedreferenceDundar Y, Greenhalgh J, Richardson M, Dwan K. Pharmacological treatment of acute agitation associated with psychotic and bipolar disorder: a systematic review and meta‐analysis. Hum Psychopharmacol. 2016; 31: 268 ‐ 85.
dc.identifier.citedreferenceGarriga M, Pacchiarotti I, Kasper S, et al. Assessment and management of agitation in psychiatry: expert consensus. World J Biol Psychiatry. 2016; 17: 86 ‐ 128.
dc.identifier.citedreferenceZimbroff DL, Marcus RN, Manos G, et al. Management of acute agitation in patients with bipolar disorder – Efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol. 2007; 27: 171 ‐ 6.
dc.identifier.citedreferenceDe Filippis S, Cuomo I, Lionetto L, et al. Intramuscular aripiprazole in the acute management of psychomotor agitation. Pharmacotherapy. 2013; 33: 603 ‐ 14.
dc.identifier.citedreferenceMeehan K, Zhang F, David S, et al. A double‐blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001; 21: 389 ‐ 97.
dc.identifier.citedreferenceCitrome L. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder. Int J Clin Pract. 2012; 66: 318 ‐ 25.
dc.identifier.citedreferenceKwentus J, Riesenberg RA, Marandi M, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo‐controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012; 14: 31 ‐ 40.
dc.identifier.citedreferenceBattaglia J, Lindborg SR, Alaka K, Meehan K, Wright P. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med. 2003; 21: 192 ‐ 8.
dc.identifier.citedreferenceBaldacara L, Sanches M, Cordeiro DC, Jackoswski AP. Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileira De Psiquiatria. 2011; 33: 30 ‐ 9.
dc.identifier.citedreferencePerrin E, Anand E, Dyachkova Y, Wagner T, Frediani S, Ballerini A. A prospective, observational study of the safety and effectiveness of intramuscular psychotropic treatment in acutely agitated patients with schizophrenia and bipolar mania. Eur Psychiatry. 2012; 27: 234 ‐ 9.
dc.identifier.citedreferenceKishi T, Matsunaga S, Iwata N. Intramuscular olanzapine for agitated patients: a systematic review and meta‐analysis of randomized controlled trials. J Psychiatr Res. 2015; 68: 198 ‐ 209.
dc.identifier.citedreferencePratts M, Citrome L, Grant W, Leso L, Opler LA. A single‐dose, randomized, double‐blind, placebo‐controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand. 2014; 130: 61 ‐ 8.
dc.identifier.citedreferenceLenox RH, Newhouse PA, Creelman WL, Whitaker TM. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double‐blind study. J Clin Psychiatry. 1992; 53: 47 ‐ 52.
dc.identifier.citedreferenceLim HK, Kim JJ, Pae CU, Lee CU, Lee C, Paik IH. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study. Neuropsychobiology. 2010; 62: 81 ‐ 6.
dc.identifier.citedreferenceMantovani C, Labate CM, Sponholz A Jr, et al. Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated‐blind trial of 4 intramuscular interventions J Clin Psychopharmacol. 2013; 33: 306 ‐ 12.
dc.identifier.citedreferenceRaveendran NS, Tharyan P, Alexander J, Adams CE. Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. BMJ. 2007; 335: 865.
dc.identifier.citedreferenceLesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short‐term management of agitated psychotic patients. J Clin Psychiatry. 2001; 62: 12 ‐ 8.
dc.identifier.citedreferenceCurrier GW, Chou JC, Feifel D, et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry. 2004; 65: 386 ‐ 94.
dc.identifier.citedreferenceVillari V, Rocca P, Fonzo V, Montemagni C, Pandullo P, Bogetto F. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32: 405 ‐ 13.
dc.identifier.citedreferenceKetter TA. Monotherapy versus combined treatment with second‐generation antipsychotics in bipolar disorder. J Clin Psychiatry. 2008; 69 ( Suppl.5 ): 9 ‐ 15.
dc.identifier.citedreferenceYildiz A, Nikodem M, Vieta E, Correll CU, Baldessarini RJ. A network meta‐analysis on comparative efficacy and all‐cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med. 2015; 45: 299 ‐ 317.
dc.identifier.citedreferenceOgawa Y, Tajika A, Takeshima N, Hayasaka Y, Furukawa T. Mood stabilizers and antipsychotics for acute mania: a systematic review and meta‐analysis of combination/augmentation therapy versus monotherapy. CNS Drugs. 2014; 28: 989 ‐ 1003.
dc.identifier.citedreferenceLin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs. 2006; 20: 29 ‐ 42.
dc.identifier.citedreferenceGeoffroy PA, Etain B, Henry C, Bellivier F. Combination therapy for manic phases: a critical review of a common practice. CNS Neurosci Ther. 2012; 18: 957 ‐ 64.
dc.identifier.citedreferenceBourin MS, Severus E, Schronen JP, et al. Lithium as add‐on to quetiapine XR in adult patients with acute mania: a 6‐week, multicenter, double‐blind, randomized, placebo‐controlled study. Int J Bipolar Disord. 2014; 2: 14.
dc.identifier.citedreferenceReischies FM, Hartikainen J, Berghoefer A. Initial lithium and valproate combination therapy in acute mania. Neuropsychobiology. 2002; 46: 22 ‐ 7.
dc.identifier.citedreferenceReischies FM, Hartikainen J, Berghofer AM. Initial triple therapy of acute mania, adding lithium and valproate to neuroleptics. Pharmacopsychiatry. 2002; 35: 244 ‐ 6.
dc.identifier.citedreferenceSharma V, Persad E, Mazmanian D, Karunaratne K. Treatment of rapid cycling bipolar disorder with combination therapy of valproate and lithium. Can J Psychiatry. 1993; 38: 137 ‐ 9.
dc.identifier.citedreferenceGranneman GR, Schneck DW, Cavanaugh JH, Witt GF. Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium. J Clin Psychiatry. 1996; 57: 204 ‐ 6.
dc.identifier.citedreferenceSikdar S, Kulhara P, Avasthi A, Singh H. Combined chlorpromazine and electroconvulsive‐therapy in mania. Br J Psychiatry. 1994; 164: 806 ‐ 10.
dc.identifier.citedreferenceSmall JG, Klapper MH, Kellams JJ, et al. Electroconvulsive treatment compared with lithium in the management of manic states. Arch Gen Psychiatry. 1988; 45: 727 ‐ 32.
dc.identifier.citedreferenceMohan TSP, Tharyan P, Alexander J, Raveendran NS. Effects of stimulus intensity on the efficacy and safety of twice‐weekly, bilateral electroconvulsive therapy (ECT) combined with antipsychotics in acute mania: a randomised controlled trial. Bipolar Disord. 2009; 11: 126 ‐ 34.
dc.identifier.citedreferenceHiremani RM, Thirthalli J, Tharayil BS, Gangadhar BN. Double‐blind randomized controlled study comparing short‐term efficacy of bifrontal and bitemporal electroconvulsive therapy in acute mania. Bipolar Disord. 2008; 10: 701 ‐ 7.
dc.identifier.citedreferenceBarekatain M, Jahangard L, Haghighi M, Ranjkesh F. Bifrontal versus bitemporal electroconvulsive therapy in severe manic patients. J ECT. 2008; 24: 199 ‐ 202.
dc.identifier.citedreferencePrien RF, Caffey EM, Klett CJ. Comparison of lithium carbonate and chlorpromazine in treatment of mania – report of veterans‐administration and National‐Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry. 1972; 26: 146 ‐ 53.
dc.identifier.citedreferenceCurtin F, Schulz P. Clonazepam and lorazepam in acute mania: a Bayesian meta‐analysis. J Affect Disord. 2004; 78: 201 ‐ 8.
dc.identifier.citedreferenceCalabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment‐refractory mania. Am J Psychiatry. 1996; 153: 759 ‐ 64.
dc.identifier.citedreferenceKimmel SE, Calabrese JR, Woyshville MJ, Meltzer HY. Clozapine in treatment‐refractory mood disorders. J Clin Psychiatry. 1994; 55: 91 ‐ 3.
dc.identifier.citedreferenceBarbini B, Scherillo P, Benedetti F, Crespi G, Colombo C, Smeraldi E. Response to clozapine in acute mania is more rapid than that of chlorpromazine. Int Clin Psychopharmacol. 1997; 12: 109 ‐ 12.
dc.identifier.citedreferenceSuppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1‐year trial of clozapine versus treatment as usual for patients with treatment‐resistant illness and a history of mania. Am J Psychiatry. 1999; 156: 1164 ‐ 9.
dc.identifier.citedreferenceJuruena MF, Ottoni GL, Machado‐Vieira R, et al. Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add‐on treatment to lithium in a double‐blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33: 94 ‐ 9.
dc.identifier.citedreferenceSachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double‐blind, placebo‐controlled comparison of efficacy and safety. Am J Psychiatry. 2002; 159: 1146 ‐ 54.
dc.identifier.citedreferenceTalaei A, Pourgholami M, Khatibi‐Moghadam H, et al. Tamoxifen: a protein kinase C inhibitor to treat mania a systematic review and meta‐analysis of randomized, placebo‐controlled trials. J Clin Psychopharmacol. 2016; 36: 272 ‐ 5.
dc.identifier.citedreferencePraharaj SK, Ram D, Arora M. Efficacy of high frequency (rapid) suprathreshold repetitive transcranial magnetic stimulation of right prefrontal cortex in bipolar mania: a randomized sham controlled study. J Affect Disord. 2009; 117: 146 ‐ 50.
dc.identifier.citedreferenceWeiser M, Burshtein S, Gershon AA, et al. Allopurinol for mania: a randomized trial of allopurinol versus placebo as add‐on treatment to mood stabilizers and/or antipsychotic agents in manic patients with bipolar disorder. Bipolar Disord. 2014; 16: 441 ‐ 7.
dc.identifier.citedreferenceGrunze H, Kotlik E, Costa R, et al. Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: experience from multicentre, double‐blind, randomised phase II clinical studies in patients with bipolar disorder I. J Affect Disord. 2015; 174: 70 ‐ 82.
dc.identifier.citedreferenceSarris J, Mischoulon D, Schweitzer I. Omega‐3 for bipolar disorder: meta‐analyses of use in mania and bipolar depression. J Clin Psychiatry. 2012; 73: 81 ‐ 6.
dc.identifier.citedreferenceBersudsky Y, Applebaum J, Gaiduk Y, et al. Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double‐blind, controlled, add‐on clinical trial. Bipolar Disord. 2010; 12: 376 ‐ 82.
dc.identifier.citedreferenceWeiser M, Levi L, Levine SZ, et al. A randomized, double‐blind, placebo‐ and risperidone‐controlled study on valnoctamide for acute mania. Bipolar Disord. 2017; 19: 285 ‐ 94.
dc.identifier.citedreferenceDauphinais D, Knable M, Rosenthal J, Polanski M, Rosenthal N. Zonisamide for bipolar disorder, mania or mixed states: a randomized, double blind, placebo‐controlled adjunctive trial. Psychopharmacol Bull. 2011; 44: 5 ‐ 17.
dc.identifier.citedreferenceTohen M, Vieta E, Goodwin GM, et al. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12‐week, double‐blind study. J Clin Psychiatry. 2008; 69: 1776 ‐ 89.
dc.identifier.citedreferenceYatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania – International, double‐blind, randomised controlled trial. Br J Psychiatry. 2003; 182: 141 ‐ 7.
dc.identifier.citedreferenceSarris J, Mischoulon D, Schweitzer I. Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: a systematic review of clinical trials. Bipolar Disord. 2011; 13: 454 ‐ 65.
dc.identifier.citedreferenceBehzadi AH, Omrani Z, Chalian M, Asadi S, Ghadiri M. Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: a double‐blind randomized controlled trial. Acta Psychiatr Scand. 2009; 120: 441 ‐ 5.
dc.identifier.citedreferenceChouinard G, Young SN, Annable L. A controlled clinical trial of l ‐tryptophan in acute mania. Biol Psychiat. 1985; 20: 546 ‐ 57.
dc.identifier.citedreferenceKulkarni J, Berk M, Wang W, et al. A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania. Psychoneuroendocrinology. 2014; 43: 52 ‐ 61.
dc.identifier.citedreferenceKulkarni J, Garland KA, Scaffidi A, et al. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology. 2006; 31: 543 ‐ 7.
dc.identifier.citedreferenceKeck PE Jr, Hsu H‐A, Papadakis K, Russo J Jr. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. Clin Neuropharmacol. 2009; 32: 199 ‐ 204.
dc.identifier.citedreferenceSchaffer A, Levitt AJ, Joffe RT. Mexiletine in treatment‐resistant bipolar disorder. J Affect Disord. 2000; 57: 249 ‐ 53.
dc.identifier.citedreferenceBersani G. Levetiracetam in bipolar spectrum disorders: first evidence of efficacy in an open, add‐ on study. Hum Psychopharmacol. 2004; 19: 355 ‐ 6.
dc.identifier.citedreferenceMishory A, Yaroslavsky Y, Bersudsky Y, Belmaker RH. Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry. 2000; 157: 463 ‐ 5.
dc.identifier.citedreferenceHenriksen TEG, Skrede S, Fasmer OB, et al. Blue‐blocking glasses as additive treatment for mania: a randomized placebo‐controlled trial. Bipolar Disord. 2016; 18: 221 ‐ 32.
dc.identifier.citedreferenceJanicak PG, Sharma RP, Pandey G, Davis JM. Verapamil for the treatment of acute mania: a double‐blind, placebo‐controlled trial. Am J Psychiatry. 1998; 155: 972 ‐ 3.
dc.identifier.citedreferenceMallinger AG, Thase ME, Haskett R, et al. Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms. Bipolar Disord. 2008; 10: 856 ‐ 66.
dc.identifier.citedreferenceWisner KL, Peindl KS, Perel JM, Hanusa BH, Piontek CM, Baab S. Verapamil treatment for women with bipolar disorder. Biol Psychiatry. 2002; 51: 745 ‐ 52.
dc.identifier.citedreferenceKusumakar V, Yatham LN, Haslam DRS, et al. Treatment of mania, mixed state, and rapid cycling. Can J Psychiatry. 1997; 42: S79 ‐ S86.
dc.identifier.citedreferenceBowden CL. Key treatment studies of lithium in manic‐depressive illness: efficacy and side effects. J Clin Psychiatry. 1998; 59: 13 ‐ 9.
dc.identifier.citedreferenceBowden CL. Clinical correlates of therapeutic response in bipolar disorder. J Affect Disord. 2001; 67: 257 ‐ 65.
dc.identifier.citedreferenceSwann AC, Bowden CL, Morris D, et al. Depression during mania – treatment response to lithium or divalproex. Arch Gen Psychiatry. 1997; 54: 37 ‐ 42.
dc.identifier.citedreferenceSwann AC. Predicting therapeutic response in acute manic episodes: data from controlled studies with divalproex. Encephale. 2001; 27: 277 ‐ 9.
dc.identifier.citedreferenceSwann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology. 2002; 26: 530 ‐ 6.
dc.identifier.citedreferenceKeck PE, McElroy SL, Strakowski SM. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry. 1998; 59: 74 ‐ 81.
dc.identifier.citedreferenceMcIntyre RS, Yoon J. Efficacy of antimanic treatments in mixed states. Bipolar Disord. 2012; 14: 22 ‐ 36.
dc.identifier.citedreferenceYatham LN, Kennedy SH, O’Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005; 7: 5 ‐ 69.
dc.identifier.citedreferenceGonzalez‐Pinto A, Galan J, Martin‐Carrasco M, Ballesteros J, Maurino J, Vieta E. Anxiety as a marker of severity in acute mania. Acta Psychiatr Scand. 2012; 126: 351 ‐ 5.
dc.identifier.citedreferenceFeske U, Frank E, Mallinger AG, et al. Anxiety as a correlate of response to the acute treatment of bipolar I disorder. Am J Psychiatry. 2000; 157: 956 ‐ 62.
dc.identifier.citedreferenceRakofsky JJ, Dunlop BW. Treating nonspecific anxiety and anxiety disorders in patients with bipolar disorder: a review. J Clin Psychiatry. 2011; 72: 81 ‐ 90.
dc.identifier.citedreferenceVieta E, Morralla C. Prevalence of mixed mania using 3 definitions. J Affect Disord. 2010; 125: 61 ‐ 73.
dc.identifier.citedreferenceReinares M, Bonnin CDM, Hidalgo‐Mazzei D, et al. Making sense of DSM‐5 mania with depressive features. Aust N Z J Psychiatry. 2015; 49: 540 ‐ 9.
dc.identifier.citedreferenceCastle DJ. Bipolar mixed states: still mixed up? Curr Opin Psychiatry. 2014; 27: 38 ‐ 42.
dc.identifier.citedreferenceFountoulakis KN, Kontis D, Gonda X, Siamouli M, Yatham LN. Treatment of mixed bipolar states. Int J Neuropsychopharmacol. 2012; 15: 1015 ‐ 26.
dc.identifier.citedreferenceMuralidharan K, Ali M, Silveira LE, et al. Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: a meta‐analysis of placebo‐controlled trials. J Affect Disord. 2013; 150: 408 ‐ 14.
dc.identifier.citedreferenceCuomo A, Nikolova VL, Yalin N, Arnone D, Fagiolini A, Young AH. Pharmacological treatment of mixed states. CNS Spectr. 2017; 22: 186 ‐ 95.
dc.identifier.citedreferenceCoryell W, Leon AC, Turvey C, Akiskal HS, Mueller T, Endicott J. The significance of psychotic features in manic episodes: a report from the NIMH collaborative study. J Affect Disord. 2001; 67: 79 ‐ 88.
dc.identifier.citedreferenceSwann AC, Daniel DG, Kochan LD, Wozniak PJ, Calabrese JR. Psychosis in mania: specificity of its role in severity and treatment response. J Clin Psychiatry. 2004; 65: 825 ‐ 9.
dc.identifier.citedreferenceToni C, Perugi G, Mata B, Madaro D, Maremmani I, Akiskal HS. Is mood‐incongruent manic psychosis a distinct subtype? Eur Arch Psychiatry Clin Neurosci. 2001; 251: 12 ‐ 7.
dc.identifier.citedreferenceTohen M, Tsuang MT, Goodwin DC. Prediction of outcome in mania by mood‐congruent or mood‐incongruent psychotic features. Am J Psychiatry. 1992; 149: 1580 ‐ 4.
dc.identifier.citedreferenceStrakowski SM, Williams JR, Sax KW, Fleck DE, DelBello MP, Bourne ML. Is impaired outcome following a first manic episode due to mood‐incongruent psychosis? J Affect Disord. 2000; 61: 87 ‐ 94.
dc.identifier.citedreferenceFennig S, Bromet EJ, Karant MT, Ram R, Jandorf L. Mood‐congruent versus mood‐incongruent psychotic symptoms in first‐admission patients with affective disorder. J Affect Disord. 1996; 37: 23 ‐ 9.
dc.identifier.citedreferenceCarlson GA, Kotov R, Chang SW, Ruggero C, Bromet EJ. Early determinants of four‐year clinical outcomes in bipolar disorder with psychosis. Bipolar Disord. 2012; 14: 19 ‐ 30.
dc.identifier.citedreferenceSmulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3‐week placebo‐controlled trial followed by a 9‐week double‐blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol. 2005; 15: 75 ‐ 84.
dc.identifier.citedreferenceHirschfeld RMA, Keck PE, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3‐week multicenter, double‐blind, placebo‐controlled trial. Am J Psychiatry. 2004; 161: 1057 ‐ 65.
dc.identifier.citedreferenceValenti M, Pacchiarotti I, Undurraga J, et al. Risk factors for rapid cycling in bipolar disorder. Bipolar Disord. 2015; 17: 549 ‐ 59.
dc.identifier.citedreferenceNierenberg AA, Akiskal HS, Angst J, et al. Bipolar disorder with frequent mood episodes in the national comorbidity survey replication (NCS‐R). Mol Psychiatry. 2010; 15: 1075 ‐ 87.
dc.identifier.citedreferenceLee S, Tsang A, Kessler RC, et al. Rapid‐cycling bipolar disorder: cross‐national community study. Br J Psychiatry. 2010; 196: 217 ‐ 25.
dc.identifier.citedreferenceCarvalho AF, Dimellis D, Gonda X, Vieta E, McIntyre RS, Fountoulakis KN. Rapid cycling in bipolar disorder: a systematic review. J Clin Psychiatry. 2014; 75: E578 ‐ E86.
dc.identifier.citedreferenceFountoulakis KN, Kontis D, Gonda X, Yatham LN. A systematic review of the evidence on the treatment of rapid cycling bipolar disorder. Bipolar Disord. 2013; 15: 115 ‐ 37.
dc.identifier.citedreferenceCalabrese JR, Shelton MD, Rapport DJ, et al. A 20‐month, double‐blind, maintenance trial of lithium versus divalproex in rapid‐cycling bipolar disorder. Am J Psychiatry. 2005; 162: 2152 ‐ 61.
dc.identifier.citedreferenceKemp DE, Gao KM, Fein EB, et al. Lamotrigine as add‐on treatment to lithium and divalproex: lessons learned from a double‐blind, placebo‐controlled trial in rapid‐cycling bipolar disorder. Bipolar Disord. 2012; 14: 780 ‐ 9.
dc.identifier.citedreferenceMurray G, Lam RW, Beaulieu S, et al. Do symptoms of bipolar disorder exhibit seasonal variation? A multisite prospective investigation Bipolar Disord. 2011; 13: 687 ‐ 95.
dc.identifier.citedreferencePost RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH Life Chart Method. J Clin Psychiatry. 2003; 64: 680 ‐ 90.
dc.identifier.citedreferenceForte A, Baldessarini RJ, Tondo L, Vazquez GH, Pompili M, Girardi P. Long‐term morbidity in bipolar‐I, bipolar‐II, and unipolar major depressive disorders. J Affect Disord. 2015; 178: 71 ‐ 8.
dc.identifier.citedreferenceYatham LN, Lecrubier Y, Fieve RR, Davis KH, Harris SD, Krishnan AA. Quality of life in patients with bipolar I depression: data from 920 patients. Bipolar Disord. 2004; 6: 379 ‐ 85.
dc.identifier.citedreferenceVojta C, Kinosian B, Glick H, Altshuler L, Bauer MS. Self‐reported quality of life across mood states in bipolar disorder. Compr Psychiatry. 2001; 42: 190 ‐ 5.
dc.identifier.citedreferenceAltshuler LL, Gitlin MJ, Mintz J, Leight KL, Frye MA. Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J Clin Psychiatry. 2002; 63: 807 ‐ 11.
dc.identifier.citedreferenceMarangell LB, Dennehy EB, Miyahara S, et al. The functional impact of subsyndromal depressive symptoms in bipolar disorder: data from STEP‐BD. J Affect Disord. 2009; 114: 58 ‐ 67.
dc.identifier.citedreferenceGitlin MJ, Miklowitz DJ. The difficult lives of individuals with bipolar disorder: a review of functional outcomes and their implications for treatment. J Affect Disord. 2017; 209: 147 ‐ 54.
dc.identifier.citedreferenceBaldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry. 2003; 64: 44 ‐ 52.
dc.identifier.citedreferenceTondo L, Pompili M, Forte A, Baldessarini RJ. Suicide attempts in bipolar disorders: comprehensive review of 101 reports. Acta Psychiatr Scand. 2016; 133: 174 ‐ 86.
dc.identifier.citedreferenceHolma KM, Haukka J, Suominen K, et al. Differences in incidence of suicide attempts between bipolar I and II disorders and major depressive disorder. Bipolar Disord. 2014; 16: 652 ‐ 61.
dc.identifier.citedreferenceBonnin CD, Gonzalez‐Pinto A, Sole B, et al. Verbal memory as a mediator in the relationship between subthreshold depressive symptoms and functional outcome in bipolar disorder. J Affect Disord. 2014; 160: 50 ‐ 4.
dc.identifier.citedreferenceMora E, Portella MJ, Forcada I, Vieta E, Mur M. Persistence of cognitive impairment and its negative impact on psychosocial functioning in lithium‐treated, euthymic bipolar patients: a 6‐year follow‐up study. Psychol Med. 2013; 43: 1187 ‐ 96.
dc.identifier.citedreferenceDemant KM, Vinberg M, Messing LV, Miskowiak KW. Assessment of subjective and objective cognitive function in bipolar disorder: correlations, predictors and the relation to psychosocial function. Psychiatry Res. 2015; 229: 565 ‐ 71.
dc.identifier.citedreferenceRock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta‐analysis. Psychol Med. 2014; 44: 2029 ‐ 40.
dc.identifier.citedreferenceDepp CA, Mausbach BT, Harmell AL, et al. Meta‐analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. Bipolar Disord. 2012; 14: 217 ‐ 26.
dc.identifier.citedreferenceKozicky J‐M, Torres IJ, Bond DJ, Lam RW, Yatham LN. Comparison of neuropsychological effects of adjunctive risperidone or quetiapine in euthymic patients with bipolar I disorder. Int Clin Psychopharmacol. 2012; 27: 91 ‐ 9.
dc.identifier.citedreferenceMiskowiak KW, Carvalho AF, Vieta E, Kessing LV. Cognitive enhancement treatments for bipolar disorder: a systematic review and methodological recommendations. Eur Neuropsychopharmacol. 2016; 26: 1541 ‐ 61.
dc.identifier.citedreferenceYatham LN, Mackala S, Basivireddy J, et al. Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open‐label, pilot study. Lancet Psychiatry. 2017; 4: 208 ‐ 17.
dc.identifier.citedreferenceManeeton N, Maneeton B, Srisurapanont M, Martin SD. Quetiapine monotherapy in acute phase for major depressive disorder: a meta‐analysis of randomized, placebo‐controlled trials. BMC Psychiatry. 2012; 12: 160.
dc.identifier.citedreferenceSelle V, Schalkwijk S, Vazquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta‐analyses of placebo‐controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry. 2014; 47: 43 ‐ 52.
dc.identifier.citedreferenceDatto C, Pottorf WJ, Feeley L, LaPorte S, Liss C. Bipolar II compared with bipolar I disorder: baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo‐controlled clinical trials of acute bipolar depression. Ann Gen Psychiatry. 2016; 15: 9.
dc.identifier.citedreferenceSrisurapanont M, Yatham LN, Zis AP. Treatment of acute bipolar depression: a review of the literature. Can J Psychiatry. 1995; 40: 533 ‐ 44.
dc.identifier.citedreferenceSachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007; 356: 1711 ‐ 22.
dc.identifier.citedreferenceNemeroff CB, Evans DL, Gyulai L, et al. Double‐blind, placebo‐controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001; 158: 906 ‐ 12.
dc.identifier.citedreferenceGeddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta‐analysis and meta‐regression of individual patient data from five randomised trials. Br J Psychiatry. 2009; 194: 4 ‐ 9.
dc.identifier.citedreferenceCalabrese JR, Bowden CL, Sachs GS, et al. A double‐blind placebo‐controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry. 1999; 60: 79 ‐ 88.
dc.identifier.citedreferenceLoebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double‐blind, placebo‐controlled study. Am J Psychiatry. 2014; 171: 169 ‐ 77.
dc.identifier.citedreferencePikalov A, Tohen M, Tsai J, Loebel A. Efficacy of lurasidone in bipolar depression: pooled results of two adjunctive studies with lithium or valproate. Bipolar Disord. 2016; 18: 178.
dc.identifier.citedreferenceGeddes JR, Gardiner A, Rendell J, et al. Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 x 2 factorial randomised trial. Lancet Psychiatry. 2016; 3: 31 ‐ 9.
dc.identifier.citedreferencevan der Loos MLM, Mulder PGH, Hartong EGTM, et al. Efficacy and safety of lamotrigine as add‐on treatment to lithium in bipolar depression: a multicenter, double‐blind, placebo‐controlled trial. J Clin Psychiatry. 2009; 70: 223 ‐ 31.
dc.identifier.citedreferenceYoung AH, McElroy SL, Bauer M, et al. A double‐blind, placebo‐controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010; 71: 150 ‐ 62.
dc.identifier.citedreferenceCalabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double‐blind, placebo‐controlled clinical trials. Bipolar Disord. 2008; 10: 323 ‐ 33.
dc.identifier.citedreferenceUnholzer S, Haen E. Retrospective analysis of therapeutic drug monitoring data for treatment of bipolar disorder with lamotrigine. Pharmacopsychiatry. 2015; 48: 211 ‐ 4.
dc.identifier.citedreferenceKemp DE, Ganocy SJ, Brecher M, et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short‐term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord. 2011; 130: 171 ‐ 9.
dc.identifier.citedreferenceGrande I, Bernardo M, Bobes J, Saiz‐Ruiz J, Alamo C, Vieta E. Antipsychotic switching in bipolar disorders: a systematic review. Int J Neuropsychopharmacol. 2014; 17: 497 ‐ 507.
dc.identifier.citedreferenceBond DJ, Lam RW, Yatham LN. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta‐analysis. J Affect Disord. 2010; 124: 228 ‐ 34.
dc.identifier.citedreferenceChiesa A, Chierzi F, De Ronchi D, Serretti A. Quetiapine for bipolar depression: a systematic review and meta‐analysis. Int Clin Psychopharmacol. 2012; 27: 76 ‐ 90.
dc.identifier.citedreferenceMcGirr A, Vohringer PA, Ghaemi SN, Lam RW, Yatham LN. Safety and efficacy of adjunctive second‐generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta‐analysis of randomised placebo‐controlled trials. Lancet Psychiatry. 2016; 3: 1138 ‐ 46.
dc.identifier.citedreferencePacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013; 170: 1249 ‐ 62.
dc.identifier.citedreferenceSchoeyen HK, Kessler U, Andreassen OA, et al. Treatment‐resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm‐based pharmacological treatment. Am J Psychiatry. 2015; 172: 41 ‐ 51.
dc.identifier.citedreferenceDurgam S, Earley W, Lipschitz A, et al. An 8‐week randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016; 173: 271 ‐ 81.
dc.identifier.citedreferenceYatham LN, Vieta E, Durgam S, et al. Efficacy of Cariprazine in Bipolar Depression: Post Hoc Band‐Pass Analyses of 2 Randomized, Double‐Blind, Placebo‐Controlled Trials. Atlanta, Georga: American Psychiatric Association Annual meeting; 2016.
dc.identifier.citedreferenceTohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine‐fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003; 60: 1079 ‐ 88.
dc.identifier.citedreferenceBrown EB, McElroy SL, Keck PE Jr, et al. A 7‐week, randomized, double‐blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006; 67: 1025 ‐ 33.
dc.identifier.citedreferenceDunn RT, Stan VA, Chriki LS, Filkowski MM, Ghaemi SN. A prospective, open‐label study of Aripiprazole mono‐ and adjunctive treatment in acute bipolar depression. J Affect Disord. 2008; 110: 70 ‐ 4.
dc.identifier.citedreferenceMcElroy SL, Suppes T, Frye MA, et al. Open‐label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial. J Affect Disord. 2007; 101: 275 ‐ 81.
dc.identifier.citedreferenceFrye MA, Grunze H, Suppes T, et al. A placebo‐controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007; 164: 1242 ‐ 9.
dc.identifier.citedreferenceCalabrese JR, Frye MA, Yang R, Ketter TA. Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double‐blind, placebo‐controlled, multicenter trial. J Clin Psychiatry. 2014; 75: 1054 ‐ 61.
dc.identifier.citedreferenceBerk M, Tiller JWG, Zhao J, Yatham LN, Malhi GS, Weiller E. Effects of asenapine in bipolar I patients meeting proxy criteria for moderate‐to‐severe mixed major depressive episodes: a post hoc analysis. J Clin Psychiatry. 2015; 76: 728 ‐ 34.
dc.identifier.citedreferenceBauer M, Berman S, Stamm T, et al. Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomized, placebo‐controlled positron emission tomography study. Mol Psychiatry. 2016; 21: 229 ‐ 36.
dc.identifier.citedreferenceStamm TJ, Lewitzka U, Sauer C, et al. Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double‐blind, placebo‐controlled study. J Clin Psychiatry. 2014; 75: 162 ‐ 8.
dc.identifier.citedreferenceGoldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double‐blind, placebo‐controlled trial of pramipexole added to mood stabilizers for treatment‐resistant bipolar depression. Am J Psychiatry. 2004; 161: 564 ‐ 6.
dc.identifier.citedreferenceZarate CA, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo‐controlled proof of concept study. Biol Psychiat. 2004; 56: 54 ‐ 60.
dc.identifier.citedreferenceMcGirr A, Karmani S, Arsappa R, et al. Clinical efficacy and safety of repetitive transcranial magnetic stimulation in acute bipolar depression. World Psychiatry. 2016; 15: 85 ‐ 6.
dc.identifier.citedreferencePost RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry. 2006; 189: 124 ‐ 31.
dc.identifier.citedreferenceHimmelhoch JM, Fuchs CZ, Symons BJ. A double‐blind‐study of tranylcypromine treatment of major anergic depression. J Nerv Ment Dis. 1982; 170: 628 ‐ 34.
dc.identifier.citedreferenceHimmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry. 1991; 148: 910 ‐ 6.
dc.identifier.citedreferenceGrosso G, Pajak A, Marventano S, et al. Role of omega‐3 fatty acids in the treatment of depressive disorders: a comprehensive meta‐analysis of randomized clinical trials. PLoS ONE. 2014; 9: e96905.
dc.identifier.citedreferenceRosenblat JD, Kakar R, Berk M, et al. Anti‐inflammatory agents in the treatment of bipolar depression: a systematic review and meta‐analysis. Bipolar Disord. 2016; 18: 89 ‐ 101.
dc.identifier.citedreferenceBerk M, Copolov DL, Dean O, et al. N‐acetyl cysteine for depressive symptoms in bipolar disorder – A double‐blind randomized placebo‐controlled trial. Biol Psychiat. 2008; 64: 468 ‐ 75.
dc.identifier.citedreferenceTseng PT, Chen YW, Tu KY, et al. Light therapy in the treatment of patients with bipolar depression: a meta‐analytic study. Eur Neuropsychopharmacol. 2016; 26: 1037 ‐ 47.
dc.identifier.citedreferenceKirino E. Efficacy of olanzapine for treating depressive episodes in bipolar disorder. Clin Neuropsychopharmacol Ther. 2014; 5: 11 ‐ 7.
dc.identifier.citedreferenceSit DK, McGowan J, Wiltrout C, et al. Adjunctive bright light therapy for bipolar depression: a randomized double‐blind placebo‐controlled trial. Am J Psychiatry. 2017; [e‐pub] appiajp201716101200.
dc.identifier.citedreferenceRomeo B, Choucha W, Fossati P, Rotge JY. Meta‐analysis of short‐ and mid‐term efficacy of ketamine in unipolar and bipolar depression. Psychiatry Res. 2015; 230: 682 ‐ 8.
dc.identifier.citedreferenceAndrade C. Ketamine for depression, 5: potential pharmacokinetic and pharmacodynamic drug interactions. J Clin Psychiatry. 2017; 78: e858 ‐ e61.
dc.identifier.citedreferenceKetter TA, Yang R, Frye MA. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder. J Affect Disord. 2015; 181: 87 ‐ 91.
dc.identifier.citedreferenceFrye MA, Amchin J, Bauer M, Adler C, Yang R, Ketter TA. Randomized, placebo‐controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments. Int J Bipolar Disord. 2015; 3: 34.
dc.identifier.citedreferenceCalabrese JR, Ketter TA, Youakim JM, Tiller JM, Yang R, Frye MA. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double‐blind, placebo‐controlled, proof‐of‐concept study. J Clin Psychiatry. 2010; 71: 1363 ‐ 70.
dc.identifier.citedreferenceViktorin A, Lichtenstein P, Thase ME, et al. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry. 2014; 171: 1067 ‐ 73.
dc.identifier.citedreferenceMcElroy SL, Weisler RH, Chang W, et al. A double‐blind, placebo‐controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010; 71: 163 ‐ 74.
dc.identifier.citedreferencePeet M. Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. Br J Psychiatry. 1994; 164: 549 ‐ 50.
dc.identifier.citedreferenceThase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in non‐psychotic bipolar I depression. J Clin Psychopharmacol. 2008; 28: 13 ‐ 20.
dc.identifier.citedreferenceFountoulakis KN, Vieta E, Schmidt F. Aripiprazole monotherapy in the treatment of bipolar disorder: a meta‐analysis. J Affect Disord. 2011; 133: 361 ‐ 70.
dc.identifier.citedreferenceSachs GS, Ice KS, Chappell PB, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar i disorder: a randomized, double‐blind, placebo‐controlled trial. J Clin Psychiatry. 2011; 72: 1413 ‐ 22.
dc.identifier.citedreferenceWatson S, Gallagher P, Porter RJ, et al. A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. Biol Psychiat. 2012; 72: 943 ‐ 9.
dc.identifier.citedreferenceSaroukhani S, Emami‐Parsa M, Modabbernia A, et al. Aspirin for treatment of lithium‐associated sexual dysfunction in men: randomized double‐blind placebo‐controlled study. Bipolar Disord. 2013; 15: 650 ‐ 6.
dc.identifier.citedreferenceNery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double‐blind, randomized, placebo‐controlled study. Hum Psychopharmacol. 2008; 23: 87 ‐ 94.
dc.identifier.citedreferenceFrye MA, Ketter TA, Kimbrell TA, et al. A placebo‐controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 2000; 20: 607 ‐ 14.
dc.identifier.citedreferenceSaricicek A, Maloney K, Muralidharan A, et al. Levetiracetam in the management of bipolar depression: a randomized, double‐blind, placebo‐controlled trial. J Clin Psychiatry. 2011; 72: 744 ‐ 50.
dc.identifier.citedreferenceMcElroy SL, Martens BE, Mori N, et al. Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo‐controlled trial. Int Clin Psychopharmacol. 2015; 30: 6 ‐ 13.
dc.identifier.citedreferenceAnand A, Gunn AD, Barkay G, et al. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double‐blind, randomized, placebo‐controlled trial. Bipolar Disord. 2012; 14: 64 ‐ 70.
dc.identifier.citedreferenceKemp DE, Schinagle M, Gao KM, et al. PPAR‐gamma agonism as a modulator of mood: proof‐of‐concept for pioglitazone in bipolar depression. CNS Drugs. 2014; 28: 571 ‐ 81.
dc.identifier.citedreferenceZeinoddini A, Sorayani M, Hassanzadeh E, et al. Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double‐blind, placebo‐controlled trial. Depress Anxiety. 2015; 32: 167 ‐ 73.
dc.identifier.citedreferenceZarate CA, Quiroz JA, Singh JB, et al. An open‐label trial of the glutamate‐modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiat. 2005; 57: 430 ‐ 2.
dc.identifier.citedreferenceShelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry. 2004; 65: 1715 ‐ 9.
dc.identifier.citedreferenceBrown ES, Park J, Marx CE, et al. A randomized, double‐blind, placebo‐controlled trial of pregnenolone for bipolar depression. Neuropsychopharmacology. 2014; 39: 2867 ‐ 73.
dc.identifier.citedreferenceLoebel A, Siu C, Rajagopalan K, Pikalov A, Cucchiaro J, Ketter TA. Recovery in bipolar depression: post‐hoc analysis of a placebo‐controlled lurasidone trial followed by a long‐term continuation study. J Affect Disord. 2015; 186: 376 ‐ 82.
dc.identifier.citedreferenceMitchell PB, Hadzi‐Pavlovic D, Evoniuk G, Calabrese JR, Bowden CL. A factor analytic study in bipolar depression, and response to lamotrigine. CNS Spectr. 2013; 18: 214 ‐ 24.
dc.identifier.citedreferencePacchiarotti I, Valenti M, Bonnin CM, et al. Factors associated with initial treatment response with antidepressants in bipolar disorder. Eur Neuropsychopharmacol. 2011; 21: 362 ‐ 9.
dc.identifier.citedreferenceCoryell W, Fiedorowicz JG, Solomon D, Leon AC, Rice JP, Keller MB. Effects of anxiety on the long‐term course of depressive disorders. Br J Psychiatry. 2012; 200: 210 ‐ 5.
dc.identifier.citedreferenceYoung LT, Cooke RG, Robb JC, Levitt AJ, Joffe RT. Anxious and nonanxious bipolar disorder. J Affect Disord. 1993; 29: 49 ‐ 52.
dc.identifier.citedreferenceLydiard RB, Culpepper L, Schioler H, Gustafsson U, Paulsson B. Quetiapine monotherapy as treatment for anxiety symptoms in patients with bipolar depression: a pooled analysis of results from 2 double‐blind, randomized, placebo‐controlled studies. Prim Care Companion J Clin Psychiatry. 2009; 11: 215 ‐ 25.
dc.identifier.citedreferenceTohen M, Calabrese J, Vieta E, et al. Effect of comorbid anxiety on treatment response in bipolar depression. J Affect Disord. 2007; 104: 137 ‐ 46.
dc.identifier.citedreferenceTsai J, Thase ME, Mao Y, Ng‐Mak D, Pikalov A, Loebel A. Lurasidone for major depressive disorder with mixed features and anxiety: a post‐hoc analysis of a randomized, placebo‐controlled study. CNS Spectr. 2017; 22: 236 ‐ 45.
dc.identifier.citedreferenceDavis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo‐controlled study. J Affect Disord. 2005; 85: 259 ‐ 66.
dc.identifier.citedreferenceGoldberg JF, Perlis RH, Bowden CL, et al. Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP‐BD. Am J Psychiatry. 2009; 166: 173 ‐ 81.
dc.identifier.citedreferenceMontgomery SA, Schatzberg AF, Guelfi JD, et al. Pharmacotherapy of depression and mixed states in bipolar disorder. J Affect Disord. 2000; 59: S39 ‐ S56.
dc.identifier.citedreferenceFornaro M, Stubbs B, De Berardis D, et al. Atypical antipsychotics in the treatment of acute bipolar depression with mixed features: a systematic review and exploratory meta‐analysis of placebo‐controlled clinical trials. Int J Mol Sci. 2016; 17: 241.
dc.identifier.citedreferenceSuppes T, Silva R, Cucchiaro J, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double‐blind, placebo‐controlled study. Am J Psychiatry. 2016; 173: 400 ‐ 7.
dc.identifier.citedreferenceThase ME, Mallinger AG, McKnight D, Himmelhoch JM. Treatment of imipramine‐resistant recurrent depression 4. A double‐blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry. 1992; 149: 195 ‐ 8.
dc.identifier.citedreferenceBlack DW, Nasrallah A. Hallucinations and delusions in 1,715 patients with unipolar and bipolar affective‐disorders. Psychopathology. 1989; 22: 28 ‐ 34.
dc.identifier.citedreferenceCalabrese JR, Suppes T, Bowden CL, et al. A double‐blind, placebo‐controlled, prophylaxis study of lamotrigine in rapid‐cycling bipolar disorder. J Clin Psychiatry. 2000; 61: 841 ‐ 50.
dc.identifier.citedreferenceEl‐Mallakh RS, Vohringer PA, Ostacher MM, et al. Antidepressants worsen rapid‐cycling course in bipolar depression: a STEP‐BD randomized clinical trial. J Affect Disord. 2015; 184: 318 ‐ 21.
dc.identifier.citedreferenceVieta E, Reinares M, Rosa AR. Staging bipolar disorder. Neurotox Res. 2011; 19: 279 ‐ 85.
dc.identifier.citedreferenceKozicky JM, Torres IJ, Silveira LE, Bond DJ, Lam RW, Yatham LN. Cognitive change in the year after a first manic episode: association between clinical outcome and cognitive performance early in the course of bipolar I disorder. J Clin Psychiatry. 2014; 75: e587 ‐ 93.
dc.identifier.citedreferenceKozicky JM, McGirr A, Bond DJ, et al. Neuroprogression and episode recurrence in bipolar I disorder: a study of gray matter volume changes in first‐episode mania and association with clinical outcome. Bipolar Disord. 2016; 18: 511 ‐ 9.
dc.identifier.citedreferenceBerk M, Berk L, Dodd S, et al. Stage managing bipolar disorder. Bipolar Disord. 2014; 16: 471 ‐ 7.
dc.identifier.citedreferenceDaglas R, Cotton SM, Allott K, et al. A single‐blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania: a 12‐month follow‐up study. Eur Psychiatry. 2016; 31: 20 ‐ 8.
dc.identifier.citedreferenceBerk M, Dandash O, Daglas R, et al. Neuroprotection after a first episode of mania: a randomized controlled maintenance trial comparing the effects of lithium and quetiapine on grey and white matter volume. Transl Psychiatry. 2017; 7: e1041.
dc.identifier.citedreferenceVazquez GH, Holtzman JN, Lolich M, Ketter TA, Baldessarini RJ. Recurrence rates in bipolar disorder: systematic comparison of long‐term prospective, naturalistic studies versus randomized controlled trials. Eur Neuropsychopharmacol. 2015; 25: 1501 ‐ 12.
dc.identifier.citedreferenceGignac A, McGirr A, Lam RW, Yatham LN. Recovery and recurrence following a first episode of mania: a systematic review and meta‐analysis of prospectively characterized cohorts. J Clin Psychiatry. 2015; 76: 1241 ‐ 8.
dc.identifier.citedreferenceKessing LV, Hansen MG, Andersen PK, Angst J. The predictive effect of episodes on the risk of recurrence in depressive and bipolar disorders – a life‐long perspective. Acta Psychiatr Scand. 2004; 109: 339 ‐ 44.
dc.identifier.citedreferencePerlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP‐BD). Am J Psychiatry. 2006; 163: 217 ‐ 24.
dc.identifier.citedreferenceYen S, Stout R, Hower H, et al. The influence of comorbid disorders on the episodicity of bipolar disorder in youth. Acta Psychiatr Scand. 2016; 133: 324 ‐ 34.
dc.identifier.citedreferenceJudd LL, Schettler PJ, Akiskal HS, et al. Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Arch Gen Psychiatry. 2008; 65: 386 ‐ 94.
dc.identifier.citedreferenceDe Dios C, Ezquiaga E, Agud JL, Vieta E, Soler B, Garcia‐Lopez A. Subthreshold symptoms and time to relapse/recurrence in a community cohort of bipolar disorder outpatients. J Affect Disord. 2012; 143: 160 ‐ 5.
dc.identifier.citedreferenceCohen AN, Hammen C, Henry RM, Daley SE. Effects of stress and social support on recurrence in bipolar disorder. J Affect Disord. 2004; 82: 143 ‐ 7.
dc.identifier.citedreferenceBerk L, Hallam KT, Colom F, et al. Enhancing medication adherence in patients with bipolar disorder. Hum Psychopharmacol. 2010; 25: 1 ‐ 16.
dc.identifier.citedreferenceBerk M, Berk L, Castle D. A collaborative approach to the treatment alliance in bipolar disorder. Bipolar Disord. 2004; 6: 504 ‐ 18.
dc.identifier.citedreferenceVelligan DI, Weiden PJ, Sajatovic M, et al. Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract. 2010; 16: 34 ‐ 45.
dc.identifier.citedreferenceLingam R, Scott J. Treatment non‐adherence in affective disorders. Acta Psychiatr Scand. 2002; 105: 164 ‐ 72.
dc.identifier.citedreferenceSajatovic M, Valenstein M, Blow F, Ganoczy D, Ignacio R. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatr Serv. 2007; 58: 855 ‐ 63.
dc.identifier.citedreferenceMoon E, Chang JS, Kim MY, et al. Dropout rate and associated factors in patients with bipolar disorders. J Affect Disord. 2012; 141: 47 ‐ 54.
dc.identifier.citedreferenceBaker JP. Outcomes of lithium discontinuation – a metaanalysis. Lithium. 1994; 5: 187 ‐ 92.
dc.identifier.citedreferenceSuppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry. 1991; 48: 1082 ‐ 8.
dc.identifier.citedreferenceFaedda GL, Tondo L, Baldessarini RJ, Suppes T, Tohen M. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry. 1993; 50: 448 ‐ 55.
dc.identifier.citedreferenceSharma P, Kongasseri S, Praharaj SK. Outcome of mood stabilizer discontinuation in bipolar disorder after 5 years of euthymia. J Clin Psychopharmacol. 2014; 34: 504 ‐ 7.
dc.identifier.citedreferenceFranks MA, Macritchie KAN, Mahmood T, Young AH. Bouncing back: is the bipolar rebound phenomenon peculiar to lithium? A retrospective naturalistic study. J Psychopharmacol. 2008; 22: 452 ‐ 6.
dc.identifier.citedreferenceScott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry. 2002; 63: 384 ‐ 90.
dc.identifier.citedreferenceHong J, Reed C, Novick D, Maria Haro J, Windmeijer F, Knapp M. The cost of relapse for patients with a manic/mixed episode of bipolar disorder in the EMBLEM study. Pharmacoeconomics. 2010; 28: 555 ‐ 66.
dc.identifier.citedreferenceBaldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long‐term lithium treatment: a meta‐analytic review. Bipolar Disord. 2006; 8: 625 ‐ 39.
dc.identifier.citedreferenceLeclerc E, Mansur RB, Brietzke E. Determinants of adherence to treatment in bipolar disorder: a comprehensive review. J Affect Disord. 2013; 149: 247 ‐ 52.
dc.identifier.citedreferenceMacDonald L, Chapman S, Syrett M, Bowskill R, Horne R. Improving medication adherence in bipolar disorder: a systematic review and meta‐analysis of 30 years of intervention trials. J Affect Disord. 2016; 194: 202 ‐ 21.
dc.identifier.citedreferenceCrowe M, Wilson L, Inder M. Patients’ reports of the factors influencing medication adherence in bipolar disorder – An integrative review of the literature. Int J Nurs Stud. 2011; 48: 894 ‐ 903.
dc.identifier.citedreferenceSajatovic M, Davies M, Hrouda DR. Enhancement of treatment adherence among patients with bipolar disorder. Psychiatr Serv. 2004; 55: 264 ‐ 9.
dc.identifier.citedreferenceVelligan DI, Weiden PJ, Sajatovic M, et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract. 2010; 16: 306 ‐ 24.
dc.identifier.citedreferenceHayes JF, Marston L, Walters K, Geddes JR, King M. Osborn DPJ. lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population‐based UK cohort study using electronic health records. World Psychiatry. 2016; 15: 53 ‐ 8.
dc.identifier.citedreferenceKessing LV, Hellmund G, Andersen PK. Predictors of excellent response to lithium: results from a nationwide register‐based study. Int Clin Psychopharmacol. 2011; 26: 323 ‐ 8.
dc.identifier.citedreferenceKessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK. Valproate V. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register‐based cohort study. Br J Psychiatry. 2011; 199: 57 ‐ 63.
dc.identifier.citedreferenceGoodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA J Am Med Assoc. 2003; 290: 1467 ‐ 73.
dc.identifier.citedreferenceHayes JF, Pitman A, Marston L, et al. Self‐harm, unintentional injury, and suicide in bipolar disorder during maintenance mood stabilizer treatment: a UK population‐based electronic health records study. JAMA Psychiatry. 2016; 73: 630 ‐ 7.
dc.identifier.citedreferenceBaldessarini RJ, Tondo L. Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry. 2000; 57: 187 ‐ 90.
dc.identifier.citedreferenceRybakowski JK, Chlopocka‐Wozniak M, Suwalska A. The prophylactic effect of long‐term lithium administration in bipolar patients entering treatment in the 1970s and 1980s. Bipolar Disord. 2001; 3: 63 ‐ 7.
dc.identifier.citedreferencePeselow ED, Clevenger S, IsHak WW. Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: a naturalistic study. Int Clin Psychopharmacol. 2016; 31: 218 ‐ 23.
dc.identifier.citedreferenceAltshuler L, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1‐year follow‐up. Am J Psychiatry. 2003; 160: 1252 ‐ 62.
dc.identifier.citedreferenceYatham LN, Beaulieu S, Schaffer A, et al. Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: a CANMAT randomized double‐blind trial. Mol Psychiatry. 2016; 21: 1050 ‐ 6.
dc.identifier.citedreferenceSeverus E, Taylor M, Sauer C, Pfennig A, Bauer M, Geddes J. Efficacy of lithium in the long‐term treatment of bipolar disorders: a new meta‐analysis. Bipolar Disord. 2014; 16: 96.
dc.identifier.citedreferenceMiura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta‐analysis. Lancet Psychiatry. 2014; 1: 351 ‐ 9.
dc.identifier.citedreferenceWeisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B. Trial 144 study I. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry. 2011; 72: 1452 ‐ 64.
dc.identifier.citedreferenceCipriani A, Reid K, Young AH, Macritchie K, Geddes J. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2013;( 10 ): CD003196.
dc.identifier.citedreferenceBowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo‐controlled 12‐month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry. 2000; 57: 481 ‐ 9.
dc.identifier.citedreferenceCalabrese JR, Goldberg JF, Ketter TA, et al. Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double‐blind maintenance studies. Biol Psychiatry. 2006; 59: 1061 ‐ 4.
dc.identifier.citedreferenceSzegedi A, Durgam S, Mackle M, et al. Randomized, double‐blind, placebo‐controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder. Am J Psychiatry. 2018; 175: 71 ‐ 9.
dc.identifier.citedreferenceKeck PE, Calabrese JR, McQuade RD, et al. A randomized, double‐blind, placebo‐controlled 26‐week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006; 67: 626 ‐ 37.
dc.identifier.citedreferenceKeck PE Jr, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100‐week, double‐blind study versus placebo. J Clin Psychiatry. 2007; 68: 1480 ‐ 91.
dc.identifier.citedreferenceCalabrese JR, Sanchez R, Jin N, et al. Efficacy and safety of aripiprazole once‐monthly in the maintenance treatment of bipolar I disorder: a double‐blind, placebo‐controlled, 52‐week randomized withdrawal study. J Clin Psychiatry. 2017; 78: 324 ‐ 31.
dc.identifier.citedreferenceSuppes T, Vieta E, Liu S, Brecher M, Paulsson B, Trial I. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (Trial 127). Am J Psychiatry. 2009; 166: 476 ‐ 88.
dc.identifier.citedreferenceVieta E, Suppes T, Eggens I, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 2008; 109: 251 ‐ 63.
dc.identifier.citedreferenceMarcus R, Khan A, Rollin L, et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long‐term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double‐blind, randomized study. Bipolar Disord. 2011; 13: 133 ‐ 44.
dc.identifier.citedreferenceTohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo‐controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006; 163: 247 ‐ 56.
dc.identifier.citedreferenceVieta E, Montgomery S, Sulaiman AH, et al. A randomized, double‐blind, placebo‐controlled trial to assess prevention of mood episodes with risperidone long‐acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol. 2012; 22: 825 ‐ 35.
dc.identifier.citedreferenceQuiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V. Risperidone long‐acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiat. 2010; 68: 156 ‐ 62.
dc.identifier.citedreferenceMacfadden W, Alphs L, Haskins JT, et al. A randomized, double‐blind, placebo‐controlled study of maintenance treatment with adjunctive risperidone long‐acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord. 2009; 11: 827 ‐ 39.
dc.identifier.citedreferencePost RM, Speer AM, Obrocea GV, Leverich GS. Acute and prophylactic effects of anticonvulsants in bipolar depression. Clin Neurosci Res. 2002; 2: 228 ‐ 51.
dc.identifier.citedreferenceBerwaerts J, Melkote R, Nuamah I, Lim P. A randomized, placebo‐ and active‐controlled study of paliperidone extended‐release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. J Affect Disord. 2012; 138: 247 ‐ 58.
dc.identifier.citedreferenceBowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6‐month, randomized, placebo‐controlled, double‐blind trial. J Clin Psychiatry. 2010; 71: 130 ‐ 7.
dc.identifier.citedreferenceCalabrese JR, Pikalov A, Streicher C, Cucchiaro J, Mao Y, Loebel A. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol. 2017; 27: 865 ‐ 876.
dc.identifier.citedreferenceCarlson BX, Ketter TA, Sun W, et al. Aripiprazole in combination with lamotrigine for the long‐term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double‐blind study (CN138‐392). Bipolar Disord. 2012; 14: 41 ‐ 53.
dc.identifier.citedreferenceVieta E, Goikolea JM, Martinez‐Aran A, et al. A double‐blind, randomized, placebo‐controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. J Clin Psychiatry. 2006; 67: 473 ‐ 7.
dc.identifier.citedreferenceBrown E, Dunner DL, McElroy SL, et al. Olanzapine/fluoxetine combination vs. lamotrigine in the 6‐month treatment of bipolar I depression. Int J Neuropsychopharmacol. 2009; 12: 773 ‐ 82.
dc.identifier.citedreferenceSachs GS, Greenberg WM, Starace A, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double‐blind, placebo‐controlled, phase III trial. J Affect Disord. 2015; 174: 296 ‐ 302.
dc.identifier.citedreferenceAhlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manic‐depressive illness. A comparison with lithium. Acta Psychiatr Scand. 1981; 64: 226 ‐ 37.
dc.identifier.citedreferenceVasudev A, Macritchie K, Watson S, Geddes JR, Young AH. Oxcarbazepine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2008;( 1 ): CD005171.
dc.identifier.citedreferenceMazza M, Di Nicola M, Martinotti G, et al. Oxcarbazepine in bipolar disorder: a critical review of the literature. Expert Opin Pharmacother. 2007; 8: 649 ‐ 56.
dc.identifier.citedreferenceVieta E, Cruz N, Garcia‐Campayo J, et al. A double‐blind, randomized, placebo‐controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long‐term treatment of bipolar I and II disorder. Int J Neuropsychopharmacol. 2008; 11: 445 ‐ 52.
dc.identifier.citedreferenceZarate CA, Tohen M. Double‐blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry. 2004; 161: 169 ‐ 71.
dc.identifier.citedreferencePrien RF, Klett CJ, Caffey EM. Lithium‐carbonate and imipramine in prevention of affective episodes – comparison in recurrent affective illness. Arch Gen Psychiatry. 1973; 29: 420 ‐ 5.
dc.identifier.citedreferenceKane JM, Quitkin FM, Rifkin A, Ramoslorenzi JR, Nayak DD, Howard A. Lithium‐carbonate and imipramine in the prophylaxis of unipolar and bipolar‐II illness – a prospective, placebo‐controlled comparison. Arch Gen Psychiatry. 1982; 39: 1065 ‐ 9.
dc.identifier.citedreferencePrien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate‐imipramine combination. Arch Gen Psychiatry. 1984; 41: 1096 ‐ 104.
dc.identifier.citedreferenceSolomon DA, Keitner GI, Miller IW, Shea MT, Keller MB. Course of illness and maintenance treatments for patients with bipolar disorder. J Clin Psychiatry. 1995; 56: 5 ‐ 13.
dc.identifier.citedreferenceMacQueen GM, Young LT, Robb JC, Marriott M, Cooke RG, Joffe RT. Effect of number of episodes on wellbeing and functioning of patients with bipolar disorder. Acta Psychiatr Scand. 2000; 101: 374 ‐ 81.
dc.identifier.citedreferenceBaldessarini RJ, Tondo L, Baethge CJ, Lepri B, Bratti IM. Effects of treatment latency on response to maintenance treatment in manic‐depressive disorders. Bipolar Disord. 2007; 9: 386 ‐ 93.
dc.identifier.citedreferenceBerghofer A, Alda M, Adli M, et al. Long‐term effectiveness of lithium in bipolar disorder: a multicenter investigation of patients with typical and atypical features. J Clin Psychiatry. 2008; 69: 1860 ‐ 8.
dc.identifier.citedreferenceKleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology. 2000; 42: 2 ‐ 10.
dc.identifier.citedreferenceNolen WA, Weisler RH. The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double‐blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144). Bipolar Disord. 2013; 15: 100 ‐ 9.
dc.identifier.citedreferenceGoldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry. 1999; 60: 733 ‐ 40.
dc.identifier.citedreferenceRiemann G, Weisscher N, Post RM, et al. The relationship between self‐reported borderline personality features and prospective illness course in bipolar disorder. Int J Bipolar Disord. 2017; 5: 31.
dc.identifier.citedreferenceCoppen A, Standishbarry H, Bailey J, Houston G, Silcocks P, Hermon C. Does lithium reduce the mortality of recurrent mood disorders. J Affect Disord. 1991; 23: 1 ‐ 7.
dc.identifier.citedreferenceCoppen A, Farmer R. Suicide mortality in patients on lithium maintenance therapy. J Affect Disord. 1998; 50: 261 ‐ 7.
dc.identifier.citedreferenceAhrens B, Grof P, Moller HJ, Mulleroerlinghausen B, Wolf T. Extended survival of patients on long‐term lithium treatment. Can J Psychiatry. 1995; 40: 241 ‐ 6.
dc.identifier.citedreferenceAhrens B, Muller‐Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry. 2001; 34: 132 ‐ 6.
dc.identifier.citedreferenceCipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta‐analysis. BMJ. 2013; 346: f3646.
dc.identifier.citedreferenceGrof P, Alda M, Grof E, Fox D, Cameron P. The challenge of predicting response to stabilizing lithium treatment – the importance of patient selection. Br J Psychiatry. 1993; 163: 16 ‐ 9.
dc.identifier.citedreferenceCalabrese JR, Fatemi H, Kujawa M, Woyshville MJ. Predictors of response to mood stabilizers. J Clin Psychopharmacol. 1996; 16: S24 ‐ S31.
dc.identifier.citedreferenceRohayem J, Bayle JF, Richa S. Predictors of prophylactic response to lithium. Encephale. 2008; 34: 394 ‐ 9.
dc.identifier.citedreferenceGrof P, Duffy A, Cavazzoni P, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 2002; 63: 942 ‐ 7.
dc.identifier.citedreferenceIkeda A, Kato T. Biological predictors of lithium response in bipolar disorder. Psychiatry Clin Neurosci. 2003; 57: 243 ‐ 50.
dc.identifier.citedreferenceMertens J, Wang QW, Kim Y, et al. Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. Nature. 2015; 527: 95 ‐ 9.
dc.identifier.citedreferencePassmore MJ, Garnham J, Duffy A, et al. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord. 2003; 5: 110 ‐ 4.
dc.identifier.citedreferenceKetter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry. 2002; 63: 146 ‐ 51.
dc.identifier.citedreferenceVieta E, Suppes T, Ekholm B, Udd M, Gustafsson U. Long‐term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder. J Affect Disord. 2012; 142: 36 ‐ 44.
dc.identifier.citedreferenceVieta E, Suppes T. Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disord. 2008; 10: 163 ‐ 78.
dc.identifier.citedreferenceJudd LL, Akiskal HS, Schettler PJ, et al. Psychosocial disability in the course of bipolar I and II disorders – A prospective, comparative, longitudinal study. Arch Gen Psychiatry. 2005; 62: 1322 ‐ 30.
dc.identifier.citedreferenceDilsaver SC. An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009. J Affect Disord. 2011; 129: 79 ‐ 83.
dc.identifier.citedreferenceAltshuler LL, Sugar CA, McElroy SL, et al. Switch rates during acute treatment for bipolar II depression with lithium, sertraline, or the two combined: a randomized double‐blind comparison. Am J Psychiatry 2017; 173: 266 ‐ 76.
dc.identifier.citedreferenceJudd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long‐term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003; 60: 261 ‐ 9.
dc.identifier.citedreferenceKupka RW, Altshuler LL, Nolen WA, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 2007; 9: 531 ‐ 5.
dc.identifier.citedreferenceSchaffer A, Isometsa ET, Tondo L, et al. International Society for Bipolar Disorders Task Force on Suicide: meta‐analyses and meta‐regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord. 2015; 17: 1 ‐ 16.
dc.identifier.citedreferenceSani G, Tondo L, Koukopoulos A, et al. Suicide in a large population of former psychiatric inpatients. Psychiatry Clin Neurosci. 2011; 65: 286 ‐ 95.
dc.identifier.citedreferenceGreil W, Kleindienst N, Erazo N, Muller‐Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol. 1998; 18: 455 ‐ 60.
dc.identifier.citedreferenceMcElroy SL, Martens BE, Creech RS, et al. Randomized, double‐blind, placebo‐controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate‐to‐severe hypomania or mild mania. J Clin Psychiatry. 2010; 71: 557 ‐ 65.
dc.identifier.citedreferenceMagalhaes P, Dean OM, Bush AI, et al. A preliminary investigation on the efficacy of N‐acetyl cysteine for mania or hypomania. Aust N Z J Psychiatry. 2013; 47: 564 ‐ 8.
dc.identifier.citedreferenceMcElroy SL, Martens BE, Winstanley EL, Creech R, Malhotra S, Keck PE Jr. Placebo‐controlled study of quetiapine monotherapy in ambulatory bipolar spectrum disorder with moderate‐to‐severe hypomania or mild mania. J Affect Disord. 2010; 124: 157 ‐ 63.
dc.identifier.citedreferenceThomson M, Sharma V. Between a rock‐a‐bye and a hard place: mood disorders during the perinatal period. CNS Spectr. 2000; 22: 49 ‐ 64.
dc.identifier.citedreferenceSuppes T, Ketter TA, Gwizdowski IS, et al. First controlled treatment trial of bipolar II hypomania with mixed symptoms: quetiapine versus placebo. J Affect Disord. 2013; 150: 37 ‐ 43.
dc.identifier.citedreferenceVieta E, Gasto C, Colom F, et al. Role of risperidone in bipolar II: an open 6‐month study. J Affect Disord. 2001; 67: 213 ‐ 9.
dc.identifier.citedreferenceYoung AH, Calabrese JR, Gustafsson U, et al. Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. Int J Bipolar Disord. 2013; 1: 10.
dc.identifier.citedreferenceCalabrese JR, Keck PE, Macfadden W, et al. A randomized, double‐blind, placebo‐controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005; 162: 1351 ‐ 60.
dc.identifier.citedreferenceThase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression – A double‐blind, placebo‐controlled study (The BOLDER II study). J Clin Psychopharmacol. 2006; 26: 600 ‐ 9.
dc.identifier.citedreferenceSuppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010; 121: 106 ‐ 15.
dc.identifier.citedreferenceJeong JH, Bahk WM, Woo YS, et al. Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open‐label, observational study. Neuropsychiatr Dis Treat. 2013; 9: 197 ‐ 204.
dc.identifier.citedreferenceAhn YM, Nam JY, Culver JL, Marsh WK, Bonner JC, Ketter TA. Lamotrigine plus quetiapine combination therapy in treatment‐resistant bipolar depression. Ann Clin Psychiatry. 2011; 23: 17 ‐ 24.
dc.identifier.citedreferenceAmsterdam J. Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode. J Clin Psychopharmacol. 1998; 18: 414 ‐ 7.
dc.identifier.citedreferenceAmsterdam JD, Garcia‐Espana F. Venlafaxine monotherapy in women with bipolar II and unipolar major depression. J Affect Disord. 2000; 59: 225 ‐ 9.
dc.identifier.citedreferenceSuppes T, Marangell LB, Bernstein IH, et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J Affect Disord. 2008; 111: 334 ‐ 43.
dc.identifier.citedreferenceDonnelly EF, Goodwin FK, Waldman IN, Murphy DL. Prediction of antidepressant responses to lithium. Am J Psychiatry. 1978; 135: 552 ‐ 6.
dc.identifier.citedreferenceGoodwin FK, Murphy DL, Bunney WE. Lithium‐carbonate treatment in depression and mania – a longitudinal double‐blind study. Arch Gen Psychiatry. 1969; 21: 486 ‐ 496.
dc.identifier.citedreferenceGoodwin FK, Bunney WE, Dunner DL, Murphy DL. Lithium Response in unipolar versus bipolar depression. Am J Psychiatry. 1972; 129: 44 ‐ 7.
dc.identifier.citedreferenceBaron M, Gershon ES, Rudy V, Jonas WZ, Buchsbaum M. Lithium‐carbonate response in depression – prediction by unipolar bipolar illness, average‐evoked response, catechol‐o‐methyl transferase, and family history. Arch Gen Psychiatry. 1975; 32: 1107 ‐ 11.
dc.identifier.citedreferenceAmsterdam JD, Lorenzo‐Luaces L, Soeller I, Li SQ, Mao JJ, DeRubeis RJ. Short‐term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate. Br J Psychiatry. 2016; 208: 359 ‐ 65.
dc.identifier.citedreferenceFieve RR, Kumbaraci T, Dunner DL. Lithium prophylaxis of depression in bipolar‐1, bipolar‐2, and unipolar patients. Am J Psychiatry. 1976; 133: 925 ‐ 9.
dc.identifier.citedreferenceDunner DL, Fieve RR. Clinical factors in lithium‐carbonate prophylaxis failure. Arch Gen Psychiatry. 1974; 30: 229 ‐ 33.
dc.identifier.citedreferenceNierenberg AA, McElroy SL, Friedman ES, et al. Bipolar CHOICE (clinical health outcomes initiative in comparative effectiveness): a pragmatic 6‐month trial of lithium versus quetiapine for bipolar disorder. J Clin Psychiatry. 2016; 77: 90 ‐ 9.
dc.identifier.citedreferenceBond DJ, Noronha MM, Kauer‐Sant’Anna M, Lam RW, Yatham LN. Antidepressant‐associated mood elevations in bipolar II disorder compared with bipolar i disorder and major depressive disorder: a systematic review and meta‐analysis. J Clin Psychiatry. 2008; 69: 1589 ‐ 601.
dc.identifier.citedreferenceVohringer PA, Ostacher MJ, El‐Mallakh RS, et al. Antidepressants in type II versus type I bipolar depression a randomized discontinuation trial. J Clin Psychopharmacol. 2015; 35: 605 ‐ 8.
dc.identifier.citedreferenceAmsterdam JD, Wang C‐H, Shwarz M, Shults J. Venlafaxine versus lithium monotherapy of rapid and non‐rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open‐label trial. J Affect Disord. 2009; 112: 219 ‐ 30.
dc.identifier.citedreferenceAmsterdam JD, Luo LL, Shults J. Effectiveness and mood conversion rate of short‐term fluoxetine monotherapy in patients with rapid cycling bipolar II depression versus patients with nonrapid cycling bipolar II depression. J Clin Psychopharmacol. 2013; 33: 420 ‐ 4.
dc.identifier.citedreferenceAmsterdam JD, Luo LL, Shults J. Efficacy and mood conversion rate during long‐term fluoxetine v. lithium monotherapy in rapid‐ and non‐rapid‐cycling bipolar II disorder. Br J Psychiatry. 2013; 202: 301 ‐ 6.
dc.identifier.citedreferenceCalabrese JR, Bowden CL, Sachs G, et al. A placebo‐controlled 18‐month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003; 64: 1013 ‐ 24.
dc.identifier.citedreferenceProvencher MD, Hawke LD, Thienot E. Psychotherapies for comorbid anxiety in bipolar spectrum disorders. J Affect Disord. 2011; 133: 371 ‐ 80.
dc.identifier.citedreferenceSmith LA, Cornelius VR, Azorin JM, et al. Valproate for the treatment of acute bipolar depression: systematic review and meta‐analysis. J Affect Disord. 2010; 122: 1 ‐ 9.
dc.identifier.citedreferenceSachs GS. A 25‐year‐old woman with bipolar disorder. JAMA. 2001; 285: 454 ‐ 62.
dc.identifier.citedreferenceMuzina DJ, Gao K, Kemp DE, et al. Acute efficacy of divalproex sodium versus placebo in mood stabilizer‐naive bipolar I or II depression: a double‐blind, randomized, placebo‐controlled trial. J Clin Psychiatry. 2011; 72: 813 ‐ 9.
dc.identifier.citedreferenceYoung LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis‐Siotis I. Double‐blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry. 2000; 157: 124 ‐ 6.
dc.identifier.citedreferenceWinsberg ME, DeGolia SG, Strong CM, Ketter TA. Divalproex therapy in medication‐naive and mood‐stabilizer‐naive bipolar II depression. J Affect Disord. 2001; 67: 207 ‐ 12.
dc.identifier.citedreferenceWang PW, Nowakowska C, Chandler RA, et al. Divalproex extended‐release in acute bipolar II depression. J Affect Disord. 2010; 124: 170 ‐ 3.
dc.identifier.citedreferenceFrankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double‐blind placebo‐controlled pilot study. J Clin Psychiatry. 2002; 63: 442 ‐ 6.
dc.identifier.citedreferenceAmsterdam JD, Shults J, Brunswick DJ, Hundert M. Short‐term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression – low manic switch rate. Bipolar Disord. 2004; 6: 75 ‐ 81.
dc.identifier.citedreferenceAmsterdam JD, Garcia‐Espana F, Fawcett J, et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol. 1998; 18: 435 ‐ 40.
dc.identifier.citedreferenceAmsterdam JD, Shults J. Efficacy and safety of long‐term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double‐blind, placebo‐substitution study. Am J Psychiatry. 2010; 167: 792 ‐ 800.
dc.identifier.citedreferencePatkar A, Gilmer W, Pae CU, et al. A 6 week randomized double‐blind placebo‐controlled trial of ziprasidone for the acute depressive mixed state. PLoS ONE. 2012; 7: e34757.
dc.identifier.citedreferenceLiebowitz MR, Salman E, Mech A, et al. Ziprasidone monotherapy in bipolar II depression: an open trial. J Affect Disord. 2009; 118: 205 ‐ 8.
dc.identifier.citedreferenceFornaro M, McCarthy MJ, De Berardis D, et al. Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study. Neuropsychiatr Dis Treat. 2013; 9: 243 ‐ 51.
dc.identifier.citedreferenceStoll AL, Severus WE, Freeman MP, et al. Omega 3 fatty acids in bipolar disorder – A preliminary double‐blind, placebo‐controlled trial. Arch Gen Psychiatry. 1999; 56: 407 ‐ 12.
dc.identifier.citedreferenceFrangou S, Lewis M, McCrone P. Efficacy of ethyl‐eicosapentaenoic acid in bipolar depression: randomised double‐blind placebo‐controlled study. Br J Psychiatry. 2006; 188: 46 ‐ 50.
dc.identifier.citedreferenceKeck PE, Mintz J, McElroy SL, et al. Double‐blind, randomized, placebo‐controlled trials of ethyl‐eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiat. 2006; 60: 1020 ‐ 2.
dc.identifier.citedreferenceMagalhaes PV, Dean OM, Bush AI, et al. N‐acetyl cysteine add‐on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo‐controlled trial. J Affect Disord. 2011; 129: 317 ‐ 20.
dc.identifier.citedreferenceDiazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add‐on trial of an N ‐methyl‐ d ‐aspartate antagonist in treatment‐resistant bipolar depression. Arch Gen Psychiatry. 2010; 67: 793 ‐ 802.
dc.identifier.citedreferenceZarate CA, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add‐on trial. Biol Psychiat. 2012; 71: 939 ‐ 46.
dc.identifier.citedreferenceMcClure D, Greenman SC, Koppolu SS, Varvara M, Yaseen ZS, Galynker II. A pilot study of safety and efficacy of cranial electrotherapy stimulation in treatment of bipolar II depression. J Nerv Ment Dis. 2015; 203: 827 ‐ 35.
dc.identifier.citedreferenceKelly TF, Lieberman DZ. The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS. J Affect Disord. 2014; 167: 333 ‐ 5.
dc.identifier.citedreferenceDauphinais DR, Rosenthal JZ, Terman M, DiFebo HM, Tuggle C, Rosenthal NE. Controlled trial of safety and efficacy of bright light therapy vs. negative air ions in patients with bipolar depression. Psychiatry Res. 2012; 196: 57 ‐ 61.
dc.identifier.citedreferenceSit D, Wisner KL, Hanusa BH, Stull S, Terman M. Light therapy for bipolar disorder: a case series in women. Bipolar Disord. 2007; 9: 918 ‐ 27.
dc.identifier.citedreferenceWu JC, Kelsoe JR, Schachat C, et al. Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. Biol Psychiat. 2009; 66: 298 ‐ 301.
dc.identifier.citedreferenceColombo C, Lucca A, Benedetti F, Barbini B, Campori E, Smeraldi E. Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression: replication of main effects and interaction. Psychiatry Res. 2000; 95: 43 ‐ 53.
dc.identifier.citedreferenceBenedetti F, Colombo C, Pontiggia A, Bernasconi A, Florita M, Smeraldi E. Morning light treatment hastens the antidepressant effect of citalopram: a placebo‐controlled trial. J Clin Psychiatry. 2003; 64: 648 ‐ 53.
dc.identifier.citedreferenceDaryani KK, Bokade NK, Raichandani OP. A comparative study of efficacy of lamotrigine and levetiracetam in the continuous maintenance phase of patients with bipolar depressive disorder. Int J Bioassay. 2014; 3: 3062 ‐ 3065.
dc.identifier.citedreferenceLipinski JF, Cohen BM, Frankenburg F, et al. Open trial of S‐adenosylmethionine for treatment of depression. Am J Psychiatry. 1984; 141: 448 ‐ 50.
dc.identifier.citedreferenceCarney MWP, Chary TKN, Bottiglieri T, Reynolds EH. The switch mechanism and the bipolar unipolar dichotomy. Br J Psychiatry. 1989; 154: 48 ‐ 51.
dc.identifier.citedreferenceMurphy BL, Babb SM, Ravichandran C, Cohen BM. Oral SAMe in persistent treatment‐refractory bipolar depression a double‐blind, randomized clinical trial. J Clin Psychopharmacol. 2014; 34: 413 ‐ 6.
dc.identifier.citedreferenceBrennan BP, Jensen JE, Hudson JI, et al. A placebo‐controlled trial of acetyl‐ l ‐carnitine and alpha‐lipoic acid in the treatment of bipolar depression. J Clin Psychopharmacol. 2013; 33: 627 ‐ 35.
dc.identifier.citedreferenceHu SH, Lai JB, Xu DR, et al. Efficacy of repetitive transcranial magnetic stimulation with quetiapine in treating bipolar II depression: a randomized, double‐blinded, control study. Sci Rep. 2016; 6: 30537.
dc.identifier.citedreferenceGilmer WS, Lorenzen KM, Zarnicki J. Transcranial magnetic stimulation (TMS) for treatment resistant bipolar depression: a naturalistic case series with clinical outcomes and observations. Bipolar Disord. 2013; 15: 80 ‐ 1.
dc.identifier.citedreferenceLee SY, Chen SL, Chang YH, et al. The effects of add‐on low‐dose memantine on cytokine levels in bipolar II depression: a 12‐week double‐ blind, randomized controlled trial. J Clin Psychopharmacol. 2014; 34: 337 ‐ 43.
dc.identifier.citedreferenceYoung AH, McElroy SL, Olausson B, Paulsson BR, Embolden IDCI. Embolden IIDCI. A randomised, placebo‐controlled 52‐week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World J Biol Psychiatry. 2014; 15: 96 ‐ 112.
dc.identifier.citedreferenceCalabrese JR, Rapport DJ, Youngstrom EA, Jackson K, Bilali S, Findling RL. New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder. Eur Psychiatry. 2005; 20: 92 ‐ 5.
dc.identifier.citedreferenceAmsterdam JD, Lorenzo‐Luaces L, Soeller I, Li SQ, Mao JJ, DeRubeis RJ. Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse‐prevention of bipolar II depression: a randomized, double‐blind, parallel‐group, prospective study. J Affect Disord. 2015; 185: 31 ‐ 7.
dc.identifier.citedreferenceTondo L, Baldessarini RJ, Floris G. Long‐term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders. Br J Psychiatry. 2001; 178: S184 ‐ S90.
dc.identifier.citedreferenceSuppes T, Brown ES, McElroy SL, et al. Lamotrigine for the treatment of bipolar disorder: a clinical case series. J Affect Disord. 1999; 53: 95 ‐ 8.
dc.identifier.citedreferenceChang JS, Moon E, Cha B, Ha K. Adjunctive lamotrigine therapy for patients with bipolar II depression partially responsive to mood stabilizers. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 34: 1322 ‐ 6.
dc.identifier.citedreferenceSharma V, Khan M, Corpse C. Role of lamotrigine in the management of treatment‐resistant bipolar II depression: a chart review. J Affect Disord. 2008; 111: 100 ‐ 5.
dc.identifier.citedreferenceJung IK, Lee MS, Kang BJ, Kim MJ, Lee JH. Lamotrigine treatment for patients with bipolar ii disorder: retrospective report of 30 cases. Bipolar Disord. 2008; 10: 45 ‐ 6.
dc.identifier.citedreferenceAmsterdam JD, Shults J. Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double‐blind, placebo‐substitution, continuation study. Int Clin Psychopharmacol. 2005; 20: 257 ‐ 64.
dc.identifier.citedreferenceBowden CL, Singh V, Weisler R, et al. Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo‐controlled maintenance treatment for bipolar depression. Acta Psychiatr Scand. 2012; 126: 342 ‐ 50.
dc.identifier.citedreferenceParker G, Tully L, Olley A, Hadzi‐Pavlovic D. SSRIs as mood stabilizers for bipolar II disorder? A proof of concept study. J Affect Disord. 2006; 92: 205 ‐ 14.
dc.identifier.citedreferencePan PY, Lee MS, Lo MC, Yang EL, Yeh CB. Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study. BMC Psychiatry. 2014; 14: 145.
dc.identifier.citedreferenceViguera AC, Cohen LS, Bouffard S, Whitfield TH, Baldessarini RJ. Reproductive decisions by women with bipolar disorder after prepregnancy psychiatric consultation. Am J Psychiatry. 2002; 159: 2102 ‐ 4.
dc.identifier.citedreferenceRusner M, Berg M, Begley C. Bipolar disorder in pregnancy and childbirth: a systematic review of outcomes. BMC Pregnancy Childbirth. 2016; 16: 331.
dc.identifier.citedreferenceBoden R, Lundgren M, Brandt L, Reutfors J, Andersen M, Kieler H. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ. 2012; 345: e7085.
dc.identifier.citedreferenceJoffe H. Reproductive biology and psychotropic treatments in premenopausal women with bipolar disorder. J Clin Psychiatry. 2007; 68: 10 ‐ 5.
dc.identifier.citedreferenceViguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007; 164: 1817 ‐ 24.
dc.identifier.citedreferenceFreeman MP, Smith KW, Freeman SA, et al. The impact of reproductive events on the course of bipolar disorder in women. J Clin Psychiatry. 2002; 63: 284 ‐ 7.
dc.identifier.citedreferenceViguera AC, Nonacs R, Cohen LS, Tondo L, Murray A, Baldessarini RJ. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry. 2000; 157: 179 ‐ 84.
dc.identifier.citedreferenceIqbal MM, Gundlapalli SP, Ryan WG, Ryals T, Passman TE. Effects of antimanic mood‐stabilizing drugs on fetuses, neonates, and nursing infants. South Med J. 2001; 94: 304 ‐ 22.
dc.identifier.citedreferenceYonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry. 2004; 161: 608 ‐ 20.
dc.identifier.citedreferenceSabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res. 2001; 47: 151 ‐ 4.
dc.identifier.citedreferenceCrawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs. 2002; 16: 263 ‐ 72.
dc.identifier.citedreferencePatel N, Viguera AC, Baldessarini RJ. Mood‐stabilising anticonvulsants, spina bifida, and folate supplementation: commentary. J Clin Psychopharmacol. 2018; 38: 7 ‐ 10.
dc.identifier.citedreferenceHealth Product InfoWatch. https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/health-product-infowatch/health-product-infowatch-april-2017-page-2.html. Accessed January 30, 2018.
dc.identifier.citedreferenceKuehn BM. No easy answers for physicians caring for pregnant women with depression. JAMA. 2009; 302 ( 2413–4 ): 2420.
dc.identifier.citedreferenceFrey BN, Simpson W, Wright L, Steiner M. Sensitivity and specificity of the Mood Disorder Questionnaire as a screening tool for bipolar disorder during pregnancy and the postpartum period. J Clin Psychiatry. 2012; 73: 1456 ‐ 61.
dc.identifier.citedreferenceSharma V, Xie B. Screening for postpartum bipolar disorder: validation of the Mood Disorder Questionnaire. J Affect Disord. 2011; 131: 408 ‐ 11.
dc.identifier.citedreferenceClark CT, Sit DK, Driscoll K, et al. Does screening with the MDQ and EPDS improve identification of bipolar disorder in an obstetrical sample? Depress Anxiety. 2015; 32: 518 ‐ 26.
dc.identifier.citedreferenceMerrill L, Mittal L, Nicoloro J, Caiozzo C, Maciejewski PK, Miller LJ. Screening for bipolar disorder during pregnancy. Arch Womens Ment Health. 2015; 18: 579 ‐ 83.
dc.identifier.citedreferenceWisner KL, Sit DK, McShea MC, et al. Onset timing, thoughts of self‐harm, and diagnoses in postpartum women with screen‐positive depression findings. JAMA Psychiatry. 2013; 70: 490 ‐ 8.
dc.identifier.citedreferenceSharma V, Pope CJ. Pregnancy and bipolar disorder: a systematic review. J Clin Psychiatry. 2012; 73: 1447 ‐ 55.
dc.identifier.citedreferencePatorno E, Huybrechts KF, Bateman BT, et al. Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med. 2017; 376: 2245 ‐ 54.
dc.identifier.citedreferenceErnst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad‐spectrum psychotropics. J Clin Psychiatry. 2002; 63: 42 ‐ 55.
dc.identifier.citedreferenceJentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med. 2010; 362: 2185 ‐ 93.
dc.identifier.citedreferenceMeador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009; 360: 1597 ‐ 605.
dc.identifier.citedreferenceInformation for healthcare professionals: risk of neural tube birth defects following prenatal exposure to valproate. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm192649.htm. Accessed December 4, 2017.
dc.identifier.citedreferenceFreedman R, Ross RG. Prenatal choline and the development of schizophrenia. Shanghai Arch Psychiatry. 2015; 27: 90 ‐ 102.
dc.identifier.citedreferenceRaghavan R, Riley AW, Volk H, et al. Maternal multivitamin intake, plasma folate and vitamin b12 levels and autism spectrum disorder risk in offspring. Paediatr Perinat Epidemiol. 2017; 32: 100 ‐ 11.
dc.identifier.citedreferenceWesseloo R, Kamperman AM, Munk‐Olsen T, Pop VJM, Kushner SA, Bergink V. Risk of postpartum relapse in bipolar disorder and postpartum psychosis: a systematic review and meta‐analysis. Am J Psychiatry. 2016; 173: 117 ‐ 27.
dc.identifier.citedreferenceBergink V, Burgerhout KM, Koorengevel KM, et al. Treatment of psychosis and mania in the postpartum period. Am J Psychiatry. 2015; 172: 115 ‐ 23.
dc.identifier.citedreferenceSharma V, Khan M, Sommerdyk C. Quetiapine in the acute treatment of bipolar postpartum depression a chart review. J Clin Psychopharmacol. 2015; 35: 733 ‐ 5.
dc.identifier.citedreferenceSharma V, Doobay M, Baczynski C. Bipolar postpartum depression: an update and recommendations. J Affect Disord. 2017; 219: 105 ‐ 11.
dc.identifier.citedreferenceHeron J, McGuinness M, Blackmore ER, Craddock N, Jones I. Early postpartum symptoms in puerperal psychosis. BJOG. 2008; 115: 348 ‐ 53.
dc.identifier.citedreferenceMenon SJ. Psychotropic medication during pregnancy and lactation. Arch Gynecol Obstet. 2008; 277: 1 ‐ 13.
dc.identifier.citedreferencePacchiarotti I, Leon‐Caballero J, Murru A, et al. Mood stabilizers and antipsychotics during breastfeeding: focus on bipolar disorder. Eur Neuropsychopharmacol. 2016; 26: 1562 ‐ 78.
dc.identifier.citedreferenceWard RM, Bates BA, Benitz WE, et al. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001; 108: 776 ‐ 89.
dc.identifier.citedreferenceSharma V, Xie B, Campbell MK, et al. A prospective study of diagnostic conversion of major depressive disorder to bipolar disorder in pregnancy and postpartum. Bipolar Disord. 2014; 16: 16 ‐ 21.
dc.identifier.citedreferenceDias RS, Lafer B, Russo C, et al. Longitudinal follow‐up of bipolar disorder in women with premenstrual exacerbation: findings from STEP‐BD. Am J Psychiatry. 2011; 168: 386 ‐ 94.
dc.identifier.citedreferenceFrey BN, Minuzzi L. Comorbid bipolar disorder and premenstrual dysphoric disorder: real patients, unanswered questions. Arch Womens Ment Health. 2013; 16: 79 ‐ 81.
dc.identifier.citedreferenceSlyepchenko A, Frey BN, Lafer B, Nierenberg AA, Sachs GS, Dias RS. Increased illness burden in women with comorbid bipolar and premenstrual dysphoric disorder: data from 1 099 women from STEP‐BD study. Acta Psychiatr Scand. 2017; 136: 473 ‐ 82.
dc.identifier.citedreferenceTeatero ML, Mazmanian D, Sharma V. Effects of the menstrual cycle on bipolar disorder. Bipolar Disord. 2014; 16: 22 ‐ 36.
dc.identifier.citedreferenceWittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med. 2002; 32: 119 ‐ 32.
dc.identifier.citedreferenceSmith M, Frey BN. Treating comorbid premenstrual dysphoric disorder in women with bipolar disorder. J Psychiatry Neurosci. 2016; 41: E22 ‐ 3.
dc.identifier.citedreferenceSajatovic M, Friedman SH, Schuermeyer IN, et al. Menopause knowledge and subjective experience among peri‐ and postmenopausal women with bipolar disorder, schizophrenia and major depression. J Nerv Ment Dis. 2006; 194: 173 ‐ 8.
dc.identifier.citedreferenceBlackmore ER, Craddock N, Walters J, Jones I. Is the perimenopause a time of increased risk of recurrence in women with a history of bipolar affective postpartum psychosis? A case series. Arch Womens Ment Health. 2008; 11: 75 ‐ 8.
dc.identifier.citedreferenceMarsh WK, Ketter TA, Crawford SL, Johnson JV, Kroll‐Desrosiers AR, Rothschild AJ. Progression of female reproductive stages associated with bipolar illness exacerbation. Bipolar Disord. 2012; 14: 515 ‐ 26.
dc.identifier.citedreferenceMarsh WK, Templeton A, Ketter TA, Rasgon NL. Increased frequency of depressive episodes during the menopausal transition in women with bipolar disorder: preliminary report. J Psychiatr Res. 2008; 42: 247 ‐ 51.
dc.identifier.citedreferenceSoares CN, Taylor V. Effects and management of the menopausal transition in women with depression and bipolar disorder. J Clin Psychiatry. 2007; 68: 16 ‐ 21.
dc.identifier.citedreferenceGoldstein BI, Birmaher B. Prevalence, clinical presentation and differential diagnosis of pediatric bipolar disorder. Isr J Psychiatry Relat Sci. 2012; 49: 3 ‐ 14.
dc.identifier.citedreferenceVan Meter AR, Moreira AL, Youngstrom EA. Meta‐analysis of epidemiologic studies of pediatric bipolar disorder. J Clin Psychiatry. 2011; 72: 1250 ‐ 6.
dc.identifier.citedreferenceVan Meter AR, Burke C, Kowatch RA, Findling RL, Youngstrom EA. Ten‐year updated meta‐analysis of the clinical characteristics of pediatric mania and hypomania. Bipolar Disord. 2016; 18: 19 ‐ 32.
dc.identifier.citedreferenceLeibenluft E, Rich BA. Pediatric bipolar disorder. Annu Rev Clin Psychol. 2008; 4: 163 ‐ 87.
dc.identifier.citedreferenceLeibenluft E, Charney DS, Towbin KE, Bhangoo RK, Pine DS. Defining clinical phenotypes of juvenile mania. Am J Psychiatry. 2003; 160: 430 ‐ 7.
dc.identifier.citedreferenceGoldstein BI, Birmaher B, Carlson GA, et al. The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research. Bipolar Disord. 2017; 19: 524 ‐ 543.
dc.identifier.citedreferencePerlis RH, Miyahara S, Marangell LB, et al. Long‐term implications of early onset in bipolar disorder: Data from the first 1000 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP‐BD). Biol Psychiat. 2004; 55: 875 ‐ 81.
dc.identifier.citedreferenceGoldstein BI, Levitt AJ. Further evidence for a developmental subtype of bipolar disorder defined by age at onset: results from the national epidemiologic survey on alcohol and related conditions. Am J Psychiatry. 2006; 163: 1633 ‐ 6.
dc.identifier.citedreferenceAxelson DA, Birmaher B, Findling RL, et al. Concerns regarding the inclusion of temper dysregulation disorder with dysphoria in the diagnostic and statistical manual of mental disorders, fifth edition. J Clin Psychiatry. 2011; 72: 1257 ‐ 62.
dc.identifier.citedreferenceBirmaher B, Axelson D, Goldstein B, et al. Four‐year longitudinal course of children and adolescents with bipolar spectrum disorders: the course and outcome of bipolar youth (COBY) study. Am J Psychiatry. 2009; 166: 795 ‐ 804.
dc.identifier.citedreferenceParens E, Johnston J. Controversies concerning the diagnosis and treatment of bipolar disorder in children. Child Adolesc Psychiatry Ment Health. 2010; 4: 9.
dc.identifier.citedreferenceKozloff N, Cheung AH, Schaffer A, et al. Bipolar disorder among adolescents and young adults: results from an epidemiological sample. J Affect Disord. 2010; 125: 350 ‐ 4.
dc.identifier.citedreferenceKhazanov GK, Cui L, Merikangas KR, Angst J. Treatment patterns of youth with bipolar disorder: results from the National Comorbidity Survey‐Adolescent Supplement (NCS‐A). J Abnorm Child Psychol. 2015; 43: 391 ‐ 400.
dc.identifier.citedreferenceGoldstein BI. Recent progress in understanding pediatric bipolar disorder. Arch Pediatr Adolesc Med. 2012; 166: 362 ‐ 71.
dc.identifier.citedreferencePost RM, Leverich GS, Kupka RW, et al. Early‐onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. J Clin Psychiatry. 2010; 71: 864 ‐ 72.
dc.identifier.citedreferenceMiller S, Chang KD, Ketter TA. Bipolar disorder and attention‐deficit/hyperactivity disorder comorbidity in children and adolescents: evidence‐based approach to diagnosis and treatment. J Clin Psychiatry. 2013; 74: 628 ‐ 9.
dc.identifier.citedreferenceFonseka TM, Swampillai B, Timmins V, et al. Significance of borderline personality‐spectrum symptoms among adolescents with bipolar disorder. J Affect Disord. 2015; 170: 39 ‐ 45.
dc.identifier.citedreferenceUchida M, Serra G, Zayas L, Kenworthy T, Faraone SV, Biederman J. Can unipolar and bipolar pediatric major depression be differentiated from each other? A systematic review of cross‐sectional studies examining differences in unipolar and bipolar depression. J Affect Disord. 2015; 176: 1 ‐ 7.
dc.identifier.citedreferenceUchida M, Serra G, Zayas L, et al. Can manic switches be predicted in pediatric major depression? A systematic literature review. J Affect Disord. 2015; 172: 300 ‐ 6.
dc.identifier.citedreferenceRatheesh A, Davey C, Hetrick S, et al. A systematic review and meta‐analysis of prospective transition from major depression to bipolar disorder. Acta Psychiatr Scand. 2017; 135: 273 ‐ 84.
dc.identifier.citedreferenceChang K, Steiner H, Dienes K, Adleman N, Ketter T. Bipolar offspring: a window into bipolar disorder evolution. Biol Psychiatry. 2003; 53: 945 ‐ 51.
dc.identifier.citedreferenceBirmaher B, Axelson D, Monk K, et al. Lifetime psychiatric disorders in school‐aged offspring of parents with bipolar disorder: the Pittsburgh Bipolar Offspring study. Arch Gen Psychiatry. 2009; 66: 287 ‐ 96.
dc.identifier.citedreferenceGoldstein BI, Shamseddeen W, Axelson DA, et al. Clinical, demographic, and familial correlates of bipolar spectrum disorders among offspring of parents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2010; 49: 388 ‐ 96.
dc.identifier.citedreferenceGoldsmith M, Singh M, Chang K. Antidepressants and psychostimulants in pediatric populations: is there an association with mania? Paediatr Drugs. 2011; 13: 225 ‐ 43.
dc.identifier.citedreferenceYoungstrom EA, Frazier TW, Demeter C, Calabrese JR, Findling RL. Developing a ten item mania scale from the parent general behavior inventory for children and adolescents. J Clin Psychiatry. 2008; 69: 831 ‐ 9.
dc.identifier.citedreferenceDiler RS, Birmaher B, Axelson D, et al. The child behavior checklist (CBCL) and the cbcl‐bipolar phenotype are not useful in diagnosing pediatric bipolar disorder. J Child Adolesc Psychopharmacol. 2009; 19: 23 ‐ 30.
dc.identifier.citedreferencePost RM, Rowe M, Kaplan D, Findling R. The child network for parents to track their child’s mood and behavior. J Child Adolesc Psychopharmacol. 2017; 27: 840 ‐ 843.
dc.identifier.citedreferenceGoldstein BI, Carnethon MR, Matthews KA, et al. Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease a scientific statement from the American Heart Association. Circulation. 2015; 132: 965 ‐ 86.
dc.identifier.citedreferenceCorrell CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo‐controlled trials. Bipolar Disord. 2010; 12: 116 ‐ 41.
dc.identifier.citedreferenceGeller B, Luby JL, Joshi P, et al. A Randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry. 2012; 69: 515 ‐ 28.
dc.identifier.citedreferenceFindling RL, Robb A, McNamara NK, et al. Lithium in the Acute treatment of bipolar I disorder: a double‐blind, placebo‐controlled study. Pediatrics. 2015; 136: 885 ‐ 94.
dc.identifier.citedreferenceHaas M, DelBello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double‐blind, placebo‐controlled study. Bipolar Disord. 2009; 11: 687 ‐ 700.
dc.identifier.citedreferenceFindling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric bipolar i disorder, manic or mixed episode, with aripiprazole: a randomized, double‐blind, placebo‐controlled study. J Clin Psychiatry. 2009; 70: 1441 ‐ 51.
dc.identifier.citedreferenceFindling RL, Landbloom RL, Szegedi A, et al. Asena pine for the acute treatment of pediatric manic or mixed episode of bipolar I disorder. J Am Acad Child Adolesc Psychiatry. 2015; 54: 1032 ‐ 41.
dc.identifier.citedreferencePathak S, Findling RL, Earley WR, Acevedo LD, Stankowski J, DelBello MP. Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3‐week, double‐blind, placebo‐controlled trial. J Clin Psychiatry. 2013; 74: E100 ‐ U47.
dc.identifier.citedreferenceTohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007; 164: 1547 ‐ 56.
dc.identifier.citedreferenceFindling RL, Cavus I, Pappadopulos E, et al. Efficacy, long‐term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2013; 23: 545 ‐ 57.
dc.identifier.citedreferenceDelBello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double‐blind, randomized, placebo‐controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002; 41: 1216 ‐ 23.
dc.identifier.citedreferenceKowatch RA, Findling RL, Scheffer RE, Stanford K. Pediatric bipolar collaborative mood stabilizer trial. Annual meeting of the American Academy of Child and Adolescent Psychiatry. Boston MA, 2007.
dc.identifier.citedreferenceWagner KD, Kowatch RA, Emslie GJ, et al. A double‐blind, randomized, placebo‐controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry. 2006; 163: 1179 ‐ 86.
dc.identifier.citedreferenceDelBello MP, Goldman R, Phillips D, Deng L, Cucchiaro J, Loebel A. Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double‐blind, placebo‐controlled study. J Am Acad Child Adolesc Psychiatry. 2017; 56: 1015 ‐ 1025.
dc.identifier.citedreferencePatel NC, Delbello MP, Bryan HS, et al. Open‐label lithium for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry. 2006; 45: 289 ‐ 97.
dc.identifier.citedreferenceChang K, Saxena K, Howe M. An open‐label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry. 2006; 45: 298 ‐ 304.
dc.identifier.citedreferenceDetke HC, DelBello MP, Landry J, Usher RW. Olanzapine/fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double‐blind, placebo‐controlled trial. J Am Acad Child Adolesc Psychiatry. 2015; 54: 217 ‐ 24.
dc.identifier.citedreferenceDelBello MP, Chang K, Welge JA, et al. A double‐blind, placebo‐controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord. 2009; 11: 483 ‐ 93.
dc.identifier.citedreferenceFindling RL, Pathak S, Earley WR, Liu S, DelBello MP. Efficacy and safety of extended‐release quetiapine fumarate in youth with bipolar depression: an 8 week, double‐blind, placebo‐controlled trial. J Child Adolesc Psychopharmacol. 2014; 24: 325 ‐ 35.
dc.identifier.citedreferenceBhowmik D, Aparasu RR, Rajan SS, Sherer JT, Ochoa‐Perez M, Chen H. Risk of manic switch associated with antidepressant therapy in pediatric bipolar depression. J Child Adolesc Psychopharmacol. 2014; 24: 551 ‐ 61.
dc.identifier.citedreferenceFindling RL, Correll CU, Nyilas M, et al. Aripiprazole for the treatment of pediatric bipolar I disorder: a 30‐week, randomized, placebo‐controlled study. Bipolar Disord. 2013; 15: 138 ‐ 49.
dc.identifier.citedreferenceFindling RL, Youngstrom EA, McNamara NK, et al. Double‐blind, randomized, placebo‐controlled long‐term maintenance study of aripiprazole in children with bipolar disorder. J Clin Psychiatry. 2012; 73: 57 ‐ 63.
dc.identifier.citedreferenceFindling RL, McNamara NK, Youngstrom EA, et al. Double‐blind 18‐month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005; 44: 409 ‐ 17.
dc.identifier.citedreferencePavuluri MN, Henry DB, Carbray JA, Naylor MW, Janicak PG. Divalproex sodium for pediatric mixed mania: a 6‐month prospective trial. Bipolar Disord. 2005; 7: 266 ‐ 73.
dc.identifier.citedreferenceKowatch RA, Suppes T, Carmody TJ, et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2000; 39: 713 ‐ 20.
dc.identifier.citedreferenceFindling RL, Chang K, Robb A, et al. Adjunctive maintenance lamotrigine for pediatric bipolar I disorder: A Placebo‐Controlled, Randomized Withdrawal Study. J Am Acad Child Adolesc Psychiatry. 2015; 54: 1020 ‐ 31.
dc.identifier.citedreferenceFindling RL, Landbloom RL, Mackle M, et al. Long‐term safety of asenapine in pediatric patients diagnosed with bipolar I disorder: A 50‐Week Open‐Label, flexible‐dose trial. Paediatr Drugs. 2016; 18: 367 ‐ 78.
dc.identifier.citedreferenceDuffy A, Milin R, Grof P. Maintenance treatment of adolescent bipolar disorder: open study of the effectiveness and tolerability of quetiapine. BMC Psychiatry. 2009; 9: 4.
dc.identifier.citedreferenceFindling RL, Pathak S, Earley WR, Liu S, DelBello M. Safety, Tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26‐week, open‐label, continuation study. J Child Adolesc Psychopharmacol. 2013; 23: 490 ‐ 501.
dc.identifier.citedreferenceScheffer RE, Kowatch RA, Carmody T, Rush AJ. Randomized, placebo‐controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry. 2005; 162: 58 ‐ 64.
dc.identifier.citedreferenceFindling RL, Short EJ, McNamara NK, et al. Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention‐deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007; 46: 1445 ‐ 53.
dc.identifier.citedreferenceViktorin A, Ryden E, Thase ME, et al. The risk of treatment‐emergent mania with methylphenidate in bipolar disorder. Am J Psychiatry. 2017; 174: 341 ‐ 8.
dc.identifier.citedreferenceHah M, Chang KK. Atomoxetine for the treatment of attention‐deficit/hyperactivity disorder in children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol. 2005; 15: 996 ‐ 1004.
dc.identifier.citedreferenceChang KK, Nayar D, Howe M, Rana M. Atomoxetine as an adjunct therapy in the treatment of co‐morbid attention‐deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder. J Child Adolesc Psychopharmacol. 2009; 19: 547 ‐ 51.
dc.identifier.citedreferencePeruzzolo TL, Tramontina S, Rodrigues RB, Rohde LA, Zeni CP. Avoiding stimulants may not prevent manic switch: a case report with atomoxetine. J Neuropsychiatry Clin Neurosci. 2014; 26: E30 ‐ 1.
dc.identifier.citedreferenceGeller B, Cooper TB, Sun K, et al. Double‐blind and placebo‐controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry. 1998; 37: 171 ‐ 8.
dc.identifier.citedreferenceGray KM, Carpenter MJ, Baker NL, et al. A double‐blind randomized controlled trial of N ‐acetylcysteine in cannabis‐dependent adolescents. Am J Psychiatry. 2012; 169: 805 ‐ 12.
dc.identifier.citedreferencePrado E, Maes M, Piccoli LG, et al. N‐acetylcysteine for therapy‐resistant tobacco use disorder: a pilot study. Redox Rep. 2015; 20: 215 ‐ 22.
dc.identifier.citedreferenceDepp CA, Jeste DV. Bipolar disorder in older adults: a critical review. Bipolar Disord. 2004; 6: 343 ‐ 67.
dc.identifier.citedreferenceYu C, Sylvestre JD, Segal M, Looper KJ, Rej S. Predictors of psychiatric re‐hospitalization in older adults with severe mental illness. Int J Geriatr Psychiatry. 2015; 30: 1114 ‐ 9.
dc.identifier.citedreferenceSajatovic M, Bingham CR, Campbell EA, Fletcher DF. Bipolar disorder in older adult inpatients. J Nerv Ment Dis. 2005; 193: 417 ‐ 9.
dc.identifier.citedreferenceJeste DV, Alexopoulos GS, Bartels SJ, et al. Consensus statement on the upcoming crisis in geriatric mental health – Research agenda for the next 2 decades. Arch Gen Psychiatry. 1999; 56: 848 ‐ 53.
dc.identifier.citedreferenceHirschfeld RMA, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. J Clin Psychiatry. 2003; 64: 53 ‐ 9.
dc.identifier.citedreferenceYassa R, Nair NPV, Iskandar H. Late‐onset bipolar disorder. Psychiatr Clin North Am. 1988; 11: 117 ‐ 31.
dc.identifier.citedreferenceSubramaniam H, Dennis MS, Byrne EJ. The role of vascular risk factors in late onset bipolar disorder. Int J Geriatr Psychiatry. 2007; 22: 733 ‐ 7.
dc.identifier.citedreferenceSajatovic M, Blow FC, Ignacio RV, Kales HC. New‐onset bipolar disorder in later life. Am J Geriatr Psychiatry. 2005; 13: 282 ‐ 9.
dc.identifier.citedreferenceDepp CA, Jin H, Mohamed S, Kaskow J, Moore DJ, Jeste DV. Bipolar disorder in middle‐aged and elderly adults: Is age of onset important? J Nerv Ment Dis. 2004; 192: 796 ‐ 9.
dc.identifier.citedreferenceYoung RC, Kiosses D, Heo M, et al. Age and ratings of manic psychopathology. Bipolar Disord. 2007; 9: 301 ‐ 4.
dc.identifier.citedreferenceOostervink F, Boomsma MM, Nolen WA, Board EA. Bipolar disorder in the elderly; different effects of age and of age of onset. J Affect Disord. 2009; 116: 176 ‐ 83.
dc.identifier.citedreferenceLala SV, Sajatovic M. Medical and psychiatric comorbidities among elderly individuals with bipolar disorder: a literature review. J Geriatr Psychiatry Neurol. 2012; 25: 20 ‐ 5.
dc.identifier.citedreferenceDepp CA, Lindamer LA, Folsom DP, et al. Differences in clinical features and mental health service use in bipolar disorder across the lifespan. Am J Geriatr Psychiatry. 2005; 13: 290 ‐ 8.
dc.identifier.citedreferenceTsai S‐Y, Lee H‐C, Chen C‐C, Huang Y‐L. Cognitive impairment in later life in patients with early‐onset bipolar disorder. Bipolar Disord. 2007; 9: 868 ‐ 75.
dc.identifier.citedreferenceGildengers AG, Chisholm D, Butters MA, et al. Two‐year course of cognitive function and instrumental activities of daily living in older adults with bipolar disorder: evidence for neuroprogression? Psychol Med. 2013; 43: 801 ‐ 11.
dc.identifier.citedreferenceSchouws S, Comijs HC, Dols A, Beekman ATF, Stek ML. Five‐year follow‐up of cognitive impairment in older adults with bipolar disorder. Bipolar Disord. 2016; 18: 148 ‐ 54.
dc.identifier.citedreferenceSantos JL, Aparicio A, Bagney A, et al. A five‐year follow‐up study of neurocognitive functioning in bipolar disorder. Bipolar Disord. 2014; 16: 722 ‐ 31.
dc.identifier.citedreferenceKessing LV, Sondergard L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry. 2008; 65: 1331 ‐ 5.
dc.identifier.citedreferenceKessing LV, Gerds TA, Knudsen NN, et al. Association of lithium in drinking water with the incidence of dementia. JAMA Psychiatry. 2017; 74: 1005 ‐ 10.
dc.identifier.citedreferenceMorris G, Berk M. The putative use of lithium in Alzheimer’s disease. Curr Alzheimer Res. 2016; 13: 853 ‐ 61.
dc.identifier.citedreferenceAndreou C, Bozikas VP. The predictive significance of neurocognitive factors for functional outcome in bipolar disorder. Curr Opin Psychiatry. 2013; 26: 54 ‐ 9.
dc.identifier.citedreferenceTsai S‐Y, Kuo C‐J, Chung K‐H, Huang Y‐L, Lee H‐C, Chen C‐C. Cognitive dysfunction and medical morbidity in elderly outpatients with bipolar disorder. Am J Geriatr Psychiatry. 2009; 17: 1004 ‐ 11.
dc.identifier.citedreferenceWestman J, Hallgren J, Wahlbeck K, Erlinge D, Alfredsson L, Osby U. Cardiovascular mortality in bipolar disorder: a population‐based cohort study in Sweden. BMJ Open. 2013; 3: e002373.
dc.identifier.citedreferenceKilbourne AM, Goodrich DE, Lai ZS, et al. Randomized controlled trial to assess reduction of cardiovascular disease risk in patients with bipolar disorder: the self‐management addressing heart risk trial (SMAHRT). J Clin Psychiatry. 2013; 74: E655 ‐ E62.
dc.identifier.citedreferenceYoung RC, Mulsant BH, Sajatovic M, et al. GERI‐BD: a randomized double‐blind controlled trial of lithium and divalproex in the treatment of mania in older patients with bipolar disorder. Am J Psychiatry. 2017; 174: 1086 ‐ 93.
dc.identifier.citedreferenceMarras C, Herrmann N, Fischer HD, et al. Lithium use in older adults is associated with increased prescribing of parkinson medications. Am J Geriatr Psychiatry. 2016; 24: 301 ‐ 9.
dc.identifier.citedreferenceKaras BJ, Wilder BJ, Hammond EJ, Bauman AW. Treatment of valproate tremors. Neurology. 1983; 33: 1380 ‐ 2.
dc.identifier.citedreferenceRej S, Elie D, Mucsi I, Looper KJ, Segal M. Chronic kidney disease in lithium‐treated older adults: a review of epidemiology, mechanisms, and implications for the treatment of late‐life mood disorders. Drugs Aging. 2015; 32: 31 ‐ 42.
dc.identifier.citedreferenceSvendal G, Fasmer OB, Engeland A, Berk M, Lund A. Co‐prescription of medication for bipolar disorder and diabetes mellitus: a nationwide population‐based study with focus on gender differences. BMC Med. 2012; 10: 148.
dc.identifier.citedreferenceDols A, Sienaert P, van Gerven H, et al. The prevalence and management of side effects of lithium and anticonvulsants as mood stabilizers in bipolar disorder from a clinical perspective: a review. Int Clin Psychopharmacol. 2013; 28: 287 ‐ 96.
dc.identifier.citedreferenceGraff‐Guerrero A, Rajji TK, Mulsant BH, et al. Evaluation of antipsychotic dose reduction in late‐life schizophrenia: a prospective dopamine D2/3 receptor occupancy study. JAMA Psychiatry. 2015; 72: 927 ‐ 34.
dc.identifier.citedreferenceMaust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015; 72: 438 ‐ 45.
dc.identifier.citedreferenceNg F, Mammen OK, Wilting I, et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord. 2009; 11: 559 ‐ 95.
dc.identifier.citedreferenceAl Jurdi RK, Marangell LB, Petersen NJ, Martinez M, Gyulai L, Sajatovic M. Prescription patterns of psychotropic medications in elderly compared with younger participants who achieved a “recovered” status in the systematic treatment enhancement program for bipolar disorder. Am J Geriatr Psychiatry. 2008; 16: 922 ‐ 33.
dc.identifier.citedreferenceSajatovic M, Strejilevich SA, Gildengers AG, et al. A report on older‐age bipolar disorder from the International Society for Bipolar Disorders Task Force. Bipolar Disord. 2015; 17: 689 ‐ 704.
dc.identifier.citedreferenceSajatovic M, Calabrese JR, Mullen J. Quetiapine for the treatment of bipolar mania in older adults. Bipolar Disord. 2008; 10: 662 ‐ 71.
dc.identifier.citedreferenceBaruch Y, Tadger S, Plopski I, Barak Y. Asenapine for elderly bipolar manic patients. J Affect Disord. 2013; 145: 130 ‐ 2.
dc.identifier.citedreferenceSajatovic M, Dines P, Fuentes‐Casiano E, et al. Asenapine in the treatment of older adults with bipolar disorder. Int J Geriatr Psychiatry. 2015; 30: 710 ‐ 9.
dc.identifier.citedreferenceSajatovic M, Coconcea N, Ignacio RV, et al. Aripiprazole therapy in 20 older adults with bipolar disorder: A 12‐week, open‐label trial. J Clin Psychiatry. 2008; 69: 41 ‐ 6.
dc.identifier.citedreferenceMadhusoodanan S, Brenner R, Araujo L, Abaza A. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry. 1995; 56: 514 ‐ 8.
dc.identifier.citedreferenceShulman RW, Singh A, Shulman KI. Treatment of elderly institutionalized bipolar patients with clozapine. Psychopharmacol Bull. 1997; 33: 113 ‐ 8.
dc.identifier.citedreferenceSajatovic M, Paulsson B. Quetiapine for the treatment of depressive episodes in adults aged 55 to 65 years with bipolar disorder. AAGP Annual Meeting. New Orleans, LA, 2007.
dc.identifier.citedreferenceSajatovic M, Forester BP, Tsai J, et al. Efficacy of lurasidone in adults aged 55 years and older with bipolar depression: post hoc analysis of 2 double‐blind, placebo‐controlled studies. J Clin Psychiatry. 2016; 77: e1324 ‐ e31.
dc.identifier.citedreferenceRobillard M, Conn DK. Lamotrigine use in geriatric patients with bipolar depression. Can J Psychiatry. 2002; 47: 767 ‐ 70.
dc.identifier.citedreferenceSajatovic M, Gildengers A, Al Jurdi RK, et al. Multisite, open‐label, prospective trial of lamotrigine for geriatric bipolar depression: a preliminary report. Bipolar Disord. 2011; 13: 294 ‐ 302.
dc.identifier.citedreferenceCullen M, Mitchell P, Brodaty H, et al. Carbamazepine for treatment‐resistant melancholia. J Clin Psychiatry. 1991; 52: 472 ‐ 6.
dc.identifier.citedreferenceRej S, Herrmann N, Shulman K, Fischer HD, Fung K, Gruneir A. Current psychotropic medication prescribing patterns in late‐life bipolar disorder. Int J Geriatr Psychiatry. 2017; 32: 1459 ‐ 1465.
dc.identifier.citedreferenceGeddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open‐label trial. Lancet. 2010; 375: 385 ‐ 95.
dc.identifier.citedreferenceSajatovic M, Gyulai L, Calabrese JR, et al. Maintenance treatment outcomes in older patients with bipolar I disorder. Am J Geriatr Psychiatry. 2005; 13: 305 ‐ 11.
dc.identifier.citedreferenceLish JD, Dimemeenan S, Whybrow PC, Price RA, Hirschfeld RMA. The National Depressive and Manic‐Depressive Association (DMDA) survey of bipolar members. J Affect Disord. 1994; 31: 281 ‐ 94.
dc.identifier.citedreferenceMcIntyre RS, Konarski JZ, Yatham LN. Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum Psychopharmacol. 2004; 19: 369 ‐ 86.
dc.identifier.citedreferenceStratford HJ, Cooper MJ, Di Simplicio M, Blackwell SE, Holmes EA. Psychological therapy for anxiety in bipolar spectrum disorders: a systematic review. Clin Psychol Rev. 2015; 35: 19 ‐ 34.
dc.identifier.citedreferenceSecades‐Alvarez A, Fernandez‐Rodriguez C. Review of the efficacy of treatments for bipolar disorder and substance abuse. Rev Psiquiatr Salud Ment. 2017; 10: 113 ‐ 24.
dc.identifier.citedreferenceHunt GE, Malhi GS, Cleary M, Lai HM, Sitharthan T. Comorbidity of bipolar and substance use disorders in national surveys of general populations, 1990‐2015: Systematic review and meta‐analysis. J Affect Disord. 2016; 206: 321 ‐ 30.
dc.identifier.citedreferenceHunt GE, Malhi GS, Cleary M, Lai HM, Sitharthan T. Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990‐2015: systematic review and meta‐analysis. J Affect Disord. 2016; 206: 331 ‐ 49.
dc.identifier.citedreferenceSonne SC, Brady KT, Morton WA. Substance‐abuse and bipolar affective‐disorder. J Nerv Ment Dis. 1994; 182: 349 ‐ 52.
dc.identifier.citedreferenceCassidy F, Ahearn EP, Carroll BJ. Substance abuse in bipolar disorder. Bipolar Disord. 2001; 3: 181 ‐ 8.
dc.identifier.citedreferenceDalton EJ, Cate‐Carter TD, Mundo E, Parikh SV, Kennedy JL. Suicide risk in bipolar patients: the role of co‐morbid substance use disorders. Bipolar Disord. 2003; 5: 58 ‐ 61.
dc.identifier.citedreferenceBeaulieu S, Saury S, Sareen J, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders. Ann Clin Psychiatry. 2012; 24: 38 ‐ 55.
dc.identifier.citedreferenceMesser T, Lammers G, Muller‐Siecheneder F, Schmidt RF, Latifi S. Substance abuse in patients with bipolar disorder: A systematic review and meta‐analysis. Psychiatry Res. 2017; 253: 338 ‐ 50.
dc.identifier.citedreferenceSoyka M, Kranzler HR, Hesselbrock V, Kasper S, Mutschler J, Moller HJ. Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. World J Biol Psychiatry. 2017; 18: 86 ‐ 119.
dc.identifier.citedreferenceKemp DE, Gao K, Ganocy SJ, et al. A 6‐month, double‐blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid‐cycling bipolar disorder and co‐occurring substance abuse or dependence. J Clin Psychiatry. 2009; 70: 113 ‐ 21.
dc.identifier.citedreferenceSalloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism – A double‐blind placebo‐controlled study. Arch Gen Psychiatry. 2005; 62: 37 ‐ 45.
dc.identifier.citedreferenceRubio G, Lopez‐Munoz F, Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord. 2006; 8: 289 ‐ 93.
dc.identifier.citedreferenceBrady KT, Sonne SC, Anton R, Ballenger JC. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry. 1995; 56: 118 ‐ 21.
dc.identifier.citedreferenceAlbanese MJ, Clodfelter RC Jr, Khantzian EJ. Divalproex sodium in substance abusers with mood disorder. J Clin Psychiatry. 2000; 61: 916 ‐ 21.
dc.identifier.citedreferenceHertzman M. Divalproex sodium to treat concomitant substance abuse and mood disorders. J Subst Abuse Treat. 2000; 18: 371 ‐ 2.
dc.identifier.citedreferenceMueser KT, Noordsy DL, Fox L, Wolfe R. Disulfiram treatment for alcoholism in severe mental illness. Am J Addictions. 2003; 12: 242 ‐ 52.
dc.identifier.citedreferenceLarson EW, Olincy A, Rummans TA, Morse RM. Disulfiram treatment of patients with both alcohol dependence and other psychiatric disorders: a review. Alcohol Clin Exp Res. 1992; 16: 125 ‐ 30.
dc.identifier.citedreferenceKofoed L, Kania J, Walsh T, Atkinson RM. Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders. Am J Psychiatry. 1986; 143: 867 ‐ 72.
dc.identifier.citedreferencePetrakis IL, Nich C, Ralevski E. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull. 2006; 32: 644 ‐ 54.
dc.identifier.citedreferencePetrakis I, Ralevski E, Nich C, et al. Naltrexone and disulfiram in patients with alcohol dependence and current depression. J Clin Psychopharmacol. 2007; 27: 160 ‐ 5.
dc.identifier.citedreferenceSonne S, Brady K. Naltrexone for individuals with comorbid bipolar disorder and alcohol dependence. J Clin Psychopharmacol. 2000; 20: 114 ‐ 5.
dc.identifier.citedreferenceBrown ES, Beard L, Dobbs L, Rush AJ. Naltrexone in patients with bipolar disorder and alcohol dependence. Depress Anxiety. 2006; 23: 492 ‐ 5.
dc.identifier.citedreferenceBrown ES, Carmody TJ, Schmitz JM, et al. A randomized, double‐blind, placebo‐controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. Alcohol Clin Exp Res. 2009; 33: 1863 ‐ 9.
dc.identifier.citedreferencePerugi G, Toni C, Frare F, et al. Effectiveness of adjunctive gabapentin in resistant bipolar disorder: Is it due to anxious‐alcohol abuse comorbidity? J Clin Psychopharmacol. 2002; 22: 584 ‐ 91.
dc.identifier.citedreferenceAzorin JM, Bowden CL, Garay RP, Perugi G, Vieta E, Young AH. Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism. Neuropsychiatr Dis Treat. 2010; 6: 37 ‐ 46.
dc.identifier.citedreferenceJonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta‐analysis. JAMA. 2014; 311: 1889 ‐ 900.
dc.identifier.citedreferenceStedman M, Pettinati HM, Brown ES, Kotz M, Calabrese JR, Raines S. A double‐blind, placebo‐controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar i patients with coexisting alcohol dependence. Alcohol Clin Exp Res. 2010; 34: 1822 ‐ 31.
dc.identifier.citedreferenceBrown ES, Davila D, Nakamura A, et al. A randomized, double‐blind, placebo‐controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence. Alcohol Clin Exp Res. 2014; 38: 2113 ‐ 8.
dc.identifier.citedreferenceGao KM, Wu RR, Kemp DE, et al. Efficacy and safety of quetiapine‐xr as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo‐controlled trial. J Clin Psychiatry. 2014; 75: 1062 ‐ 8.
dc.identifier.citedreferenceTolliver BK, DeSantis SM, Brown DG, Prisciandaro JJ, Brady KT. A randomized, double‐blind, placebo‐controlled clinical trial of acamprosate in alcohol‐dependent individuals with bipolar disorder: a preliminary report. Bipolar Disord. 2012; 14: 54 ‐ 63.
dc.identifier.citedreferenceWeinstock LM, Gaudiano BA, Wenze SJ, Epstein‐Lubow G, Miller IW. Demographic and clinical characteristics associated with comorbid cannabis use disorders (CUDs) in hospitalized patients with bipolar I disorder. Compr Psychiatry. 2016; 65: 57 ‐ 62.
dc.identifier.citedreferenceStrakowski SM, DelBello MP, Fleck DE, et al. Effects of co‐occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry. 2007; 64: 57 ‐ 64.
dc.identifier.citedreferenceBrown ES, Gorman AR, Hynan LS. A randomized, placebo‐controlled trial of citicoline add‐on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psychopharmacol. 2007; 27: 498 ‐ 502.
dc.identifier.citedreferenceBrown ES, Todd JP, Hu LT, et al. A randomized, double‐blind, placebo‐controlled trial of citicoline for cocaine dependence in bipolar I disorder. Am J Psychiatry. 2015; 172: 1014 ‐ 21.
dc.identifier.citedreferenceSalloum IM, Douaihy A, Cornelius JR, Kirisci L, Kelly TM, Hayes J. Divalproex utility in bipolar disorder with co‐occurring cocaine dependence: a pilot study. Addict Behav. 2007; 32: 410 ‐ 5.
dc.identifier.citedreferenceNunes EV, McGrath PJ, Wager S, Quitkin FM. Lithium treatment for cocaine abusers with bipolar spectrum disorders. Am J Psychiatry. 1990; 147: 655 ‐ 7.
dc.identifier.citedreferenceBrown ES, Nejtek VA, Perantie DC, Bobadilla L. Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord. 2002; 4: 406 ‐ 11.
dc.identifier.citedreferenceBrown ES, Nejtek VA, Perantie DC, Rajan Thomas N, Rush AJ. Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation. J Clin Psychopharmacol. 2003; 23: 384 ‐ 8.
dc.identifier.citedreferenceNejtek VA, Avila M, Chen L‐A, et al. Do atypical antipsychotics effectively treat co‐occurring bipolar disorder and stimulant dependence? A randomized, double‐blind trial. J Clin Psychiatry. 2008; 69: 1257 ‐ 66.
dc.identifier.citedreferenceAlbanese MJ, Suh JJ. Risperidone in cocaine‐dependent patients with comorbid psychiatric disorders. J Psychiatr Pract. 2006; 12: 306 ‐ 11.
dc.identifier.citedreferenceSepede G, Di Lorio G, Lupi M, et al. Bupropion as an add‐on therapy in depressed bipolar disorder type I patients with comorbid cocaine dependence. Clin Neuropharmacol. 2014; 37: 17 ‐ 21.
dc.identifier.citedreferenceBrown ES, Gabrielson B. A randomized, double‐blind, placebo‐controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence. J Affect Disord. 2012; 143: 257 ‐ 60.
dc.identifier.citedreferenceBrown ES, Sunderajan P, Hu LT, Sowell SM, Carmody TJ. A randomized, double‐blind, placebo‐controlled, trial of lamotrigine therapy in bipolar disorder, depressed or mixed phase and cocaine dependence. Neuropsychopharmacology. 2012; 37: 2347 ‐ 54.
dc.identifier.citedreferenceMaremmani I, Zolesi O, Aglietti M, et al. Methadone dose and retention during treatment of heroin addicts with Axis I psychiatric comorbidity. J Addict Dis. 2000; 19: 29 ‐ 41.
dc.identifier.citedreferenceMaremmani AG, Rovai L, Bacciardi S, et al. The long‐term outcomes of heroin dependent‐treatment‐resistant patients with bipolar 1 comorbidity after admission to enhanced methadone maintenance. J Affect Disord. 2013; 151: 582 ‐ 9.
dc.identifier.citedreferenceSani G, Kotzalidis GD, Vohringer P, et al. Effectiveness of short‐term olanzapine in patients with bipolar I disorder, with or without comorbidity with substance use disorder. J Clin Psychopharmacol. 2013; 33: 231 ‐ 5.
dc.identifier.citedreferenceBrown ES, Jeffress J, Liggin JD, Garza M, Beard L. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry. 2005; 66: 756 ‐ 60.
dc.identifier.citedreferenceSchaffer A, McIntosh D, Goldstein BI, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012; 24: 6 ‐ 22.
dc.identifier.citedreferenceHawke LD, Provencher MD, Parikh SV, Zagorski B. Comorbid anxiety disorders in canadians with bipolar disorder: clinical characteristics and service use. Can J Psychiatry. 2013; 58: 393 ‐ 401.
dc.identifier.citedreferenceSchaffer A, Cairney J, Veldhuizen S, Cheung A, Levitt A. Comparison of antidepressant use between subjects with bipolar disorder and major depressive disorder with or without comorbid anxiety. J Clin Psychiatry. 2007; 68: 1785 ‐ 92.
dc.identifier.citedreferenceBaldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta‐analysis. BMJ. 2011; 342: d1199.
dc.identifier.citedreferenceSheehan DV, Harnett‐Sheehan K, Hidalgo RB, et al. Randomized, placebo‐controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. J Affect Disord. 2013; 145: 83 ‐ 94.
dc.identifier.citedreferenceHirschfeld RMA, Weisler RH, Raines SR, Macfadden W, Grp BS. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: A secondary analysis from a randomized, double‐blind, placebo‐controlled study. J Clin Psychiatry. 2006; 67: 355 ‐ 62.
dc.identifier.citedreferenceSheehan DV, McElroy SL, Harnett‐Sheehan K, et al. Randomized, placebo‐controlled trial of risperidone for acute treatment of bipolar anxiety. J Affect Disord. 2009; 115: 376 ‐ 85.
dc.identifier.citedreferenceSuppes T, McElroy SL, Sheehan DV, et al. A randomized, double‐blind, placebo‐controlled study of ziprasidone monotherapy in bipolar disorder with co‐occurring lifetime panic or generalized anxiety disorder. J Clin Psychiatry. 2014; 75: 77 ‐ 84.
dc.identifier.citedreferenceMaina G, Albert U, Rosso G, Bogetto F. Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single‐blind, pilot study. J Clin Psychiatry. 2008; 69: 609 ‐ 16.
dc.identifier.citedreferenceVieta E, Martinez‐Aran A, Nieto E, et al. Adjunctive gabapentin treatment of bipolar disorder. Eur Psychiatry. 2000; 15: 433 ‐ 7.
dc.identifier.citedreferenceAmerio A, Odone A, Marchesi C, Ghaemi SN. Treatment of comorbid bipolar disorder and obsessive‐compulsive disorder: a systematic review. J Affect Disord. 2014; 166: 258 ‐ 63.
dc.identifier.citedreferenceAmerio A, Stubbs B, Odone A, Tonna M, Marchesi C, Ghaemi SN. The prevalence and predictors of comorbid bipolar disorder and obsessive‐compulsive disorder: a systematic review and meta‐analysis. J Affect Disord. 2015; 186: 99 ‐ 109.
dc.identifier.citedreferenceJeon S, Baek JH, Yang SY, et al. Exploration of comorbid obsessive‐compulsive disorder in patients with bipolar disorder: the clinic‐based prevalence rate, symptoms nature and clinical correlates. J Affect Disord. 2018; 225: 227 ‐ 33.
dc.identifier.citedreferenceNabavi B, Mitchell AJ, Nutt D. A lifetime prevalence of comorbidity between bipolar affective disorder and anxiety disorders: a meta‐analysis of 52 interview‐based studies of psychiatric population. EBioMedicine. 2015; 2: 1405 ‐ 19.
dc.identifier.citedreferenceSadock BJ, Sadock VA, Ruiz P. Kaplan and Sadock’s Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. New York: Wolters Kluwer; 2014.
dc.identifier.citedreferenceBaek JH, Cha B, Moon E, et al. The effects of ethnic, social and cultural factors on axis I comorbidity of bipolar disorder: results from the clinical setting in Korea. J Affect Disord. 2014; 166: 264 ‐ 9.
dc.identifier.citedreferenceAmerio A, Stubbs B, Odone A, Tonna M, Marchesi C, Nassir Ghaemi S. Bipolar I and II disorders: a systematic review and meta‐analysis on differences in comorbid obsessive‐compulsive disorder. Iran J Psychiatry Behav Sci. 2016; 10: e3604.
dc.identifier.citedreferenceKruger S, Braunig P, Cooke RG. Comorbidity of obsessive‐compulsive disorder in recovered inpatients with bipolar disorder. Bipolar Disord. 2000; 2: 71 ‐ 4.
dc.identifier.citedreferenceGoes FS, McCusker MG, Bienvenu OJ, et al. Co‐morbid anxiety disorders in bipolar disorder and major depression: familial aggregation and clinical characteristics of co‐morbid panic disorder, social phobia, specific phobia and obsessive‐compulsive disorder. Psychol Med. 2012; 42: 1449 ‐ 59.
dc.identifier.citedreferenceIssler CK, Monkul ES, Amaral JA, et al. Bipolar disorder and comorbid obsessive‐compulsive disorder is associated with higher rates of anxiety and impulse control disorders. Acta Neuropsychiatr. 2010; 22: 81 ‐ 6.
dc.identifier.citedreferenceMagalhaes PV, Kapczinski NS, Kapczinski F. Correlates and impact of obsessive‐compulsive comorbidity in bipolar disorder. Compr Psychiatry. 2010; 51: 353 ‐ 6.
dc.identifier.citedreferenceOzdemiroglu F, Sevincok L, Sen G, et al. Comorbid obsessive‐compulsive disorder with bipolar disorder: A distinct form? Psychiatry Res. 2015; 230: 800 ‐ 5.
dc.identifier.citedreferenceShashidhara M, Sushma BR, Viswanath B, Math SB, Janardhan Reddy YC. Comorbid obsessive compulsive disorder in patients with bipolar‐I disorder. J Affect Disord. 2015; 174: 367 ‐ 71.
dc.identifier.citedreferenceRaja M, Azzoni A. Clinical management of obsessive‐compulsive‐bipolar comorbidity: a case series. Bipolar Disord. 2004; 6: 264 ‐ 70.
dc.identifier.citedreferenceTonna M, Amerio A, Odone A, Stubbs B, Ghaemi SN. Comorbid bipolar disorder and obsessive‐compulsive disorder: which came first? Aust N Z J Psychiatry. 2016; 50: 695 ‐ 8.
dc.identifier.citedreferenceVazquez GH, Baldessarini RJ, Tondo L. Co‐occurrence of anxiety and bipolar disorders: clinical and therapeutic overview. Depress Anxiety. 2014; 31: 196 ‐ 206.
dc.identifier.citedreferenceBisol LW, Lara DR. Improvement of obsessive‐compulsive disorder with divalproex and lamotrigine in two patients with bipolar II disorder. Pharmacopsychiatry. 2009; 42: 37 ‐ 9.
dc.identifier.citedreferenceMarazziti D, Pfanner C, Dell’Osso B, et al. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long‐term open‐label study. J Psychopharmacol. 2005; 19: 392 ‐ 4.
dc.identifier.citedreferencePetrikis P, Andreou C, Bozikas VP, Karavatos A. Effective use of olanzapine for obsessive‐compulsive symptoms in a patient with bipolar disorder. Can J Psychiatry. 2004; 49: 572 ‐ 3.
dc.identifier.citedreferenceJacobsen FM. Risperidone in the treatment of affective‐illness and obsessive‐compulsive disorder. J Clin Psychiatry. 1995; 56: 423 ‐ 9.
dc.identifier.citedreferencePfanner C, Marazziti D, Dell’Osso L, et al. Risperidone augmentation in refractory obsessive‐compulsive disorder: an open‐label study. Int Clin Psychopharmacol. 2000; 15: 297 ‐ 301.
dc.identifier.citedreferenceGao K, Muzina D, Gajwani P, Calabrese JR. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: A review. J Clin Psychiatry. 2006; 67: 1327 ‐ 40.
dc.identifier.citedreferenceUguz F. Successful treatment of comorbid obsessive‐compulsive disorder with aripiprazole in three patients with bipolar disorder. Gen Hosp Psychiatry. 2010; 32: 556 ‐ 8.
dc.identifier.citedreferenceLai J, Lu Q, Zhang P, Xu T, Xu Y, Hu S. Aripiprazole augmentation in managing comorbid obsessive‐compulsive disorder and bipolar disorder: a case with suicidal attempts. Neuropsychiatr Dis Treat. 2017; 13: 87 ‐ 90.
dc.identifier.citedreferencePatra S. Treat the disease not the symptoms: successful management of obsessive compulsive disorder in bipolar disorder with aripiprazole augmentation. Aust N Z J Psychiatry. 2016; 50: 809 ‐ 10.
dc.identifier.citedreferenceBulbul F, Copoglu US, Alpak G, Unal A, Tastan MF, Savas HA. Maintenance therapy with electroconvulsive therapy in a patient with a codiagnosis of bipolar disorder and obsessive‐compulsive disorder. J ECT. 2013; 29: e21 ‐ 2.
dc.identifier.citedreferenceSahraian A, Bigdeli M, Ghanizadeh A, Akhondzadeh S. Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: A randomized double blind placebo controlled clinical trial. J Affect Disord. 2014; 166: 201 ‐ 5.
dc.identifier.citedreferenceFriborg O, Martinsen EW, Martinussen M, Kaiser S, Overgard KT, Rosenvinge JH. Comorbidity of personality disorders in mood disorders: a meta‐analytic review of 122 studies from 1988 to 2010. J Affect Disord. 2014; 152–154: 1 ‐ 11.
dc.identifier.citedreferenceRosenbluth M, MacQueen G, McIntyre RS, Beaulieu S, Schaffer A. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid personality disorders. Ann Clin Psychiatry. 2012; 24: 56 ‐ 68.
dc.identifier.citedreferencePreston GA, Marchant BK, Reimherr FW, Strong RE, Hedges DW. Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. J Affect Disord. 2004; 79: 297 ‐ 303.
dc.identifier.citedreferenceColom F, Vieta E, Sanchez‐Moreno J, et al. Psychoeducation in bipolar patients with comorbid personality disorders. Bipolar Disord. 2004; 6: 294 ‐ 8.
dc.identifier.citedreferenceAlesiani R, Boccalon S, Giarolli L, Blum N, Fossati A. Systems Training for Emotional Predictability and Problem Solving (STEPPS): program efficacy and personality features as predictors of drop‐out – an Italian study. Compr Psychiatry. 2014; 55: 920 ‐ 7.
dc.identifier.citedreferenceGoldstein TR, Axelson DA, Birmaher B, Brent DA. Dialectical behavior therapy for adolescents with bipolar disorder: A 1‐year open trial. J Am Acad Child Adolesc Psychiatry. 2007; 46: 820 ‐ 30.
dc.identifier.citedreferenceVan Dijk S, Jeffrey J, Katz MR. A randomized, controlled, pilot study of dialectical behavior therapy skills in a psychoeducational group for individuals with bipolar disorder. J Affect Disord. 2013; 145: 386 ‐ 93.
dc.identifier.citedreferenceBrus MJ, Solanto MV, Goldberg JF. Adult ADHD vs. bipolar disorder in the DSM‐5 Era: a challenging differentiation for clinicians. J Psychiatr Pract. 2014; 20: 428 ‐ 37.
dc.identifier.citedreferenceBond DJ, Hadjipavlou G, Lam RW, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention‐deficit/hyperactivity disorder. Ann Clin Psychiatry. 2012; 24: 23 ‐ 37.
dc.identifier.citedreferenceWilens TE, Prince JB, Spencer T, et al. An open trial of bupropion for the treatment of adults with attention‐deficit/hyperactivity disorder and bipolar disorder. Biol Psychiatry. 2003; 54: 9 ‐ 16.
dc.identifier.citedreferenceMcIntyre RS, Alsuwaidan M, Soczynska JK, et al. The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder. Hum Psychopharmacol. 2013; 28: 421 ‐ 7.
dc.identifier.citedreferenceWu HC, Chou FHC, Tsai KY, Su CY, Shen SP, Chung TC. The incidence and relative risk of stroke among patients with bipolar disorder: a seven‐year follow‐up study. PLoS ONE. 2013; 8: e73037.
dc.identifier.citedreferenceSmith DJ, Martin D, McLean G, Langan J, Guthrie B, Mercer SW. Multimorbidity in bipolar disorder and undertreatment of cardiovascular disease: a cross sectional study. BMC Med. 2013; 11: 263.
dc.identifier.citedreferenceForty L, Ulanova A, Jones L, et al. Comorbid medical illness in bipolar disorder. Br J Psychiatry. 2014; 205: 465 ‐ 72.
dc.identifier.citedreferenceWeber NS, Fisher JA, Cowan DN, Niebuhr DW. Psychiatric and general medical conditions comorbid with bipolar disorder in the national hospital discharge survey. Psychiatr Serv. 2011; 62: 1152 ‐ 8.
dc.identifier.citedreferenceGomes FA, Almeida KM, Magalhaes PV, et al. Cardiovascular risk factors in outpatients with bipolar disorder: a report from the Brazilian Research Network in bipolar disorder. Revista Brasileira De Psiquiatria. 2013; 35: 126 ‐ 30.
dc.identifier.citedreferenceSylvia LG, Shelton RC, Kemp DE, et al. Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE). Bipolar Disord. 2015; 17: 212 ‐ 23.
dc.identifier.citedreferenceKemp DE, Sylvia LG, Calabrese JR, et al. General medical burden in bipolar disorder: findings from the LiTMUS comparative effectiveness trial. Acta Psychiatr Scand. 2014; 129: 24 ‐ 34.
dc.identifier.citedreferenceChesney E, Goodwin GM, Fazel S. Risks of all‐cause and suicide mortality in mental disorders: a meta‐review. World Psychiatry. 2014; 13: 153 ‐ 60.
dc.identifier.citedreferenceCrump C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and mortality in bipolar disorder a Swedish national cohort study. JAMA Psychiatry. 2013; 70: 931 ‐ 9.
dc.identifier.citedreferencede Almeida KM, Moreira CL, Lafer B. Metabolic syndrome and bipolar disorder: what should psychiatrists know? CNS Neurosci Ther. 2012; 18: 160 ‐ 6.
dc.identifier.citedreferenceThird Report of the National Cholesterol Education Program. (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002; 106: 3143 ‐ 421.
dc.identifier.citedreferenceGans RO. The metabolic syndrome, depression, and cardiovascular disease: interrelated conditions that share pathophysiologic mechanisms. Med Clin North Am. 2006; 90: 573 ‐ 91.
dc.identifier.citedreferenceTaylor V, MacQueen G. Associations between bipolar disorder and metabolic syndrome: A review. J Clin Psychiatry. 2006; 67: 1034 ‐ 41.
dc.identifier.citedreferenceKrishnan KR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med. 2005; 67: 1 ‐ 8.
dc.identifier.citedreferenceMcIntyre RS, Soczynska JK, Konarski JZ, et al. Should depressive syndromes be reclassified as “metabolic syndrome type II”? Ann Clin Psychiatry. 2007; 19: 257 ‐ 64.
dc.identifier.citedreferenceKapczinski F, Vieta E, Andreazza AC, et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev. 2008; 32: 675 ‐ 92.
dc.identifier.citedreferenceMcIntyre RS, Kenna HA, Nguyen HT, et al. Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: points of pathophysiological commonality with mood disorders? Adv Ther. 2010; 27: 63 ‐ 80.
dc.identifier.citedreferenceMcIntyre RS, Alsuwaidan M, Goldstein BI, et al. The Canadian Network for Mood and Anxiety Treatments (CANWAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry. 2012; 24: 69 ‐ 81.
dc.identifier.citedreferenceDomino ME, Wells R, Morrissey JP. Serving persons with severe mental illness in primary care‐based medical homes. Psychiatr Serv. 2015; 66: 477 ‐ 83.
dc.identifier.citedreferenceSteele LS, Durbin A, Sibley LM, Glazier R. Inclusion of persons with mental illness in patient‐centred medical homes: cross‐sectional findings from Ontario, Canada. Open Med. 2013; 7: e9 ‐ 20.
dc.identifier.citedreferenceKohler‐Forsberg O, Gasse C, Berk M, Ostergaard SD. Do statins have antidepressant effects? CNS Drugs. 2017; 31: 335 ‐ 43.
dc.identifier.citedreferenceSalagre E, Fernandes BS, Dodd S, Brownstein DJ, Berk M. Statins for the treatment of depression: a meta‐analysis of randomized, double‐blind, placebo‐controlled trials. J Affect Disord. 2016; 200: 235 ‐ 42.
dc.identifier.citedreferenceWilliams LJ, Pasco JA, Mohebbi M, et al. Statin and aspirin use and the risk of mood disorders among men. Int J Neuropsychopharmacol. 2016; 19: pyw008.
dc.identifier.citedreferenceBrownstein DJ, Salagre E, Kohler C, et al. Blockade of the angiotensin system improves mental health domain of quality of life: a meta‐analysis of randomized clinical trials. Aust N Z J Psychiatry. 2018; 52: 24 ‐ 38.
dc.identifier.citedreferenceVian J, Pereira C, Chavarria V, et al. The renin‐angiotensin system: a possible new target for depression. BMC Med. 2017; 15: 144.
dc.identifier.citedreferenceWilliams LJ, Pasco JA, Kessing LV, Quirk SE, Fernandes BS, Berk M. Angiotensin converting enzyme inhibitors and risk of mood disorders. Psychother Psychosom. 2016; 85: 250 ‐ 2.
dc.identifier.citedreferenceLan CC, Liu CC, Lin CH, et al. A reduced risk of stroke with lithium exposure in bipolar disorder: a population‐based retrospective cohort study. Bipolar Disord. 2015; 17: 705 ‐ 14.
dc.identifier.citedreferenceHuang RY, Hsieh KP, Huang WW, Yang YH. Use of lithium and cancer risk in patients with bipolar disorder: population‐based cohort study. Br J Psychiatry. 2016; 209: 395 ‐ 401.
dc.identifier.citedreferenceKessing LV, Gerds TA, Feldt‐Rasmussen B, Andersen PK, Licht RW. Lithium and renal and upper urinary tract tumors – results from a nationwide population‐based study. Bipolar Disord. 2015; 17: 805 ‐ 13.
dc.identifier.citedreferenceDiniz BS, Teixeira AL, Cao F, et al. History of bipolar disorder and the risk of dementia: a systematic review and meta‐analysis. Am J Geriatr Psychiatry. 2017; 25: 357 ‐ 62.
dc.identifier.citedreferenceGerhard T, Devanand DP, Huang C, Crystal S, Olfson M. Lithium treatment and risk for dementia in adults with bipolar disorder: population‐based cohort study. Br J Psychiatry. 2015; 207: 46 ‐ 51.
dc.identifier.citedreferenceMcKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta‐analysis. Lancet. 2012; 379: 721 ‐ 8.
dc.identifier.citedreferenceLocharernkul C, Shotelersuk V, Hirankarn N. Pharmacogenetic screening of carbamazepine‐induced severe cutaneous allergic reactions. J Clin Neurosci. 2011; 18: 1289 ‐ 94.
dc.identifier.citedreferenceMalhi GS, Gessler D, Outhred T. The use of lithium for the treatment of bipolar disorder: recommendations from clinical practice guidelines. J Affect Disord. 2017; 217: 266 ‐ 80.
dc.identifier.citedreferenceGelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med. 1989; 321: 1489 ‐ 93.
dc.identifier.citedreferenceMalhi GS, Gershon S, Outhred T. Lithiumeter: version 2.0. Bipolar Disord. 2016; 18: 631 ‐ 41.
dc.identifier.citedreferenceGitlin MJ, Cochran SD, Jamison KR. Maintenance lithium treatment – side‐effects and compliance. J Clin Psychiatry. 1989; 50: 127 ‐ 31.
dc.identifier.citedreferenceAllen MH, Hirschfeld RM, Wozniak PJ, Baker JD, Bowden CL. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry. 2006; 163: 272 ‐ 5.
dc.identifier.citedreferenceHu C, Torres IJ, Qian H, et al. Trajectories of body mass index change in first episode of mania: 3‐year data from the Systematic Treatment Optimization Program for Early Mania (STOP‐EM). J Affect Disord. 2017; 208: 291 ‐ 7.
dc.identifier.citedreferenceBaldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum Psychopharmacol. 2008; 23: 95 ‐ 105.
dc.identifier.citedreferenceNemeroff CB. Safety of available agents used to treat bipolar disorder: focus on weight gain. J Clin Psychiatry. 2003; 64: 532 ‐ 9.
dc.identifier.citedreferenceFang F, Wang Z, Wu R, Calabrese JR, Gao K. Is there a ‘weight neutral’ second‐generation antipsychotic for bipolar disorder? Expert Rev Neurother. 2017; 17: 407 ‐ 18.
dc.identifier.citedreferenceOrsolini L, Tomasetti C, Valchera A, et al. An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf. 2016; 15: 1329 ‐ 47.
dc.identifier.citedreferenceBowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA. 1994; 271: 918 ‐ 24.
dc.identifier.citedreferencePersson G. Lithium side‐effects in relation to dose and to levels and gradients of lithium in plasma. Acta Psychiatr Scand. 1977; 55: 208 ‐ 13.
dc.identifier.citedreferencePersson G. Plasma lithium levels and side‐effects during administration of a slow release lithium sulfate preparation (Lithium‐lipett‐C) and lithium‐carbonate tablets. Acta Psychiatr Scand. 1974; 50: 174 ‐ 82.
dc.identifier.citedreferenceStone KA. Lithium‐induced nephrogenic diabetes insipidus. J Am Board Fam Pract. 1999; 12: 43 ‐ 7.
dc.identifier.citedreferenceBosquet S, Descombes E, Gauthier T, Fellay G, Regamey C. Nephrotic syndrome during lithium therapy. Nephrol Dial Transplant. 1997; 12: 2728 ‐ 31.
dc.identifier.citedreferenceTandon P, Wong N, Zaltzman JS. Lithium‐induced minimal change disease and acute kidney injury. N Am J Med Sci. 2015; 7: 328 ‐ 31.
dc.identifier.citedreferencePradhan BK, Chakrabarti S, Irpati AS, Bhardwaj R. Distress due to lithium‐induced polyuria: exploratory study. Psychiatry Clin Neurosci. 2011; 65: 386 ‐ 8.
dc.identifier.citedreferencePresne C, Fakhouri F, Noel LH, et al. Lithium‐induced nephropathy: rate of progression and prognostic factors. Kidney Int. 2003; 64: 585 ‐ 92.
dc.identifier.citedreferenceJohnson G. Lithium – early development, toxicity, and renal function. Neuropsychopharmacology. 1998; 19: 200 ‐ 5.
dc.identifier.citedreferenceCastro VM, Roberson AM, McCoy TH, et al. Stratifying risk for renal insufficiency among lithium‐treated patients: an electronic health record study. Neuropsychopharmacology. 2016; 41: 1138 ‐ 43.
dc.identifier.citedreferenceBocchetta A, Ardau R, Fanni T, et al. Renal function during long‐term lithium treatment: a cross‐sectional and longitudinal study. BMC Med. 2015; 13: 12.
dc.identifier.citedreferenceRej S, Herrmann N, Shulman K, et al. Lithium use, but not valproate use, is associated with a higher risk of chronic kidney disease in older adults with mental illness. J Clin Psychiatry. 2017; 78: e980 ‐ e985.
dc.identifier.citedreferenceCoresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298: 2038 ‐ 47.
dc.identifier.citedreferenceCrowe E, Halpin D, Stevens P. Early identification and management of chronic kidney disease: summary of NICE guidance. BMJ. 2008; 337: a1530.
dc.identifier.citedreferenceOkusa MD, Crystal LJT. Clinical manifestations and management of acute lithium intoxication. Am J Med. 1994; 97: 383 ‐ 9.
dc.identifier.citedreferenceTondo L, Abramowicz M, Alda M, et al. Long‐term lithium treatment in bipolar disorder: effects on glomerular filtration rate and other metabolic parameters. Int J Bipolar Disord. 2017; 5: 27.
dc.identifier.citedreferenceHaussmann R, Bauer M, von Bonin S, Grof P, Lewitzka U. Treatment of lithium intoxication: facing the need for evidence. Int J Bipolar Disord. 2015; 3: 23.
dc.identifier.citedreferenceStubner S, Grohmann R, Engel R, et al. Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry. 2004; 37: S70 ‐ S8.
dc.identifier.citedreferenceSwann AC. Major system toxicities and side effects of anticonvulsants. J Clin Psychiatry. 2001; 62: 16 ‐ 21.
dc.identifier.citedreferenceTohen M, Castillo J, Baldessarini RJ, Zarate C, Kando JC. Blood dyscrasias with carbamazepine and valproate – a pharmacoepidemiologic study of 2,228 patients at risk. Am J Psychiatry. 1995; 152: 413 ‐ 8.
dc.identifier.citedreferenceBlackburn SCF, Oliart AD, Rodriguez LAG, Gutthann SP. Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy. 1998; 18: 1277 ‐ 83.
dc.identifier.citedreferenceTrannel TJ, Ahmed I, Goebert D. Occurrence of thrombocytopenia in psychiatric patients taking valproate. Am J Psychiatry. 2001; 158: 128 ‐ 30.
dc.identifier.citedreferenceKing DJ, Wager E. Haematological safety of antipsychotic drugs. J Psychopharmacol. 1998; 12: 283 ‐ 8.
dc.identifier.citedreferenceReilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SHL. QTc‐interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000; 355: 1048 ‐ 52.
dc.identifier.citedreferenceRoose SP, Bone S, Haidorfer C, Dunner DL, Fieve RR. Lithium treatment in older patients. Am J Psychiatry. 1979; 136: 843 ‐ 4.
dc.identifier.citedreferenceFrye MA, Denicoff KD, Bryan AL, et al. Association between lower serum free T‐4 and greater mood instability and depression in lithium‐maintained bipolar patients. Am J Psychiatry. 1999; 156: 1909 ‐ 14.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bdi12609.pdf
Size:
3.424MB
Format:
PDF
View/Open
Name:
bdi12609_am.pdf
Size:
1.251MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.